Clovis Oncology (CLVSQ) 10-Q 4 Aug 21 2021 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2021	Jul. 30, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2021
Entity File Number	001-35347
Entity Registrant Name	Clovis Oncology, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	90-0475355
Entity Address, Address Line One	5500 Flatiron Parkway, Suite 100
Entity Address, City or Town	Boulder
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80301
City Area Code	303
Local Phone Number	625-5000
Title of 12(b) Security	Common Stock
Trading Symbol	CLVS
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		118,409,780
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Entity Central Index Key	0001466301
Amendment Flag	false

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenues:
Product revenue	$ 36,820	$ 39,887	$ 74,873	$ 82,451
Product revenue - extensible list	Product	Product	Product	Product
Operating expenses:
Research and development	$ 45,759	$ 69,878	$ 98,564	$ 138,099
Selling, general and administrative	32,918	41,902	62,859	84,500
Acquired in-process research and development	2,204		2,204
Other operating expenses	3,884	355	7,591	3,805
Total expenses	94,402	122,535	190,466	247,112
Operating loss	(57,582)	(82,648)	(115,593)	(164,661)
Other income (expense):
Interest expense	(8,770)	(6,739)	(16,807)	(16,300)
Foreign currency (loss) gain	(206)	142	(752)	(735)
Loss on convertible senior notes conversion				(7,791)
Loss on extinguishment of debt		(3,277)		(3,277)
Other income	107	239	290	1,081
Other income (expense), net	(8,869)	(9,635)	(17,269)	(27,022)
Loss before income taxes	(66,451)	(92,283)	(132,862)	(191,683)
Income tax benefit	3	36	137	104
Net loss	(66,448)	(92,247)	(132,725)	(191,579)
Other comprehensive income (loss):
Foreign currency translation adjustments, net of tax	14	61	(66)	(42)
Net unrealized loss on available-for-sale securities, net of tax		(84)		(6)
Other comprehensive income (loss):	14	(23)	(66)	(48)
Comprehensive loss	$ (66,434)	$ (92,270)	$ (132,791)	$ (191,627)
Loss per basic and diluted common share:
Basic net loss per common share	$ (0.61)	$ (1.15)	$ (1.25)	$ (2.52)
Diluted net loss per common share	$ (0.61)	$ (1.15)	$ (1.25)	$ (2.52)
Basic weighted average common shares outstanding	108,481	80,453	106,375	76,057
Diluted weighted average common shares outstanding	108,481	80,453	106,375	76,057
Product
Operating expenses:
Cost of sales	$ 8,294	$ 9,120	$ 16,562	$ 18,216
Intangible asset amortization
Operating expenses:
Cost of sales	$ 1,343	$ 1,280	$ 2,686	$ 2,492

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 230,204	$ 240,229
Accounts receivable, net	24,180	26,511
Inventories, net	24,993	30,714
Prepaid research and development expenses	3,920	4,245
Other current assets	13,056	9,130
Total current assets	296,353	310,829
Inventories	104,046	104,123
Property and equipment, net	7,792	12,085
Right-of-use assets, net	21,046	30,438
Intangible assets, net	63,057	65,743
Goodwill	63,074	63,074
Other assets	16,861	19,262
Total assets	572,229	605,554
Current liabilities:
Accounts payable	22,479	26,692
Accrued research and development expenses	40,065	43,500
Lease liabilities	3,572	5,330
Convertible senior notes	64,353	64,198
Other accrued expenses	43,410	45,208
Total current liabilities	173,879	184,928
Long-term lease liabilities - less current portion	21,584	31,640
Convertible senior notes - less current portion	435,759	434,846
Borrowings under financing agreement	147,365	110,917
Other long-term liabilities	625	1,971
Total liabilities	779,212	764,302
Commitments and contingencies (Note 14)
Stockholders' equity:
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized, no shares issued and outstanding at June 30, 2021 and December 31, 2020
Common stock, $0.001 par value per share, 200,000,000 shares authorized at June 30, 2021 and December 31, 2020, respectively; 118,403,984 and 103,699,109 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively	118	104
Additional paid-in capital	2,582,721	2,498,179
Accumulated other comprehensive loss	(44,370)	(44,304)
Accumulated deficit	(2,745,452)	(2,612,727)
Total stockholders' deficit	(206,983)	(158,748)
Total liabilities and stockholders' equity (deficit)	$ 572,229	$ 605,554

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2021	Dec. 31, 2020
CONSOLIDATED BALANCE SHEETS
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	118,403,984	103,699,109
Common stock, shares outstanding	118,403,984	103,699,109

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Total
Beginning Balance at Dec. 31, 2019	$ 55	$ 2,114,068	$ (44,865)	$ (2,243,515)	$ (174,257)
Beginning Balance (in shares) at Dec. 31, 2019	54,956,341
Exercise of stock options		2			2
Exercise of stock options (in shares)	759
Issuance of common stock from vesting of restricted stock units (in shares)	662,323
Share-based compensation expense		12,961			12,961
Foreign currency translation adjustments			(103)		(103)
Net unrealized gain (loss) on available-for-sale securities			78		78
Convertible senior notes conversion	$ 18	133,640			133,658
Convertible senior notes conversion (in shares)	17,877,164
Net loss				(99,332)	(99,332)
Ending Balance at Mar. 31, 2020	$ 73	2,260,671	(44,890)	(2,342,847)	(126,993)
Ending Balance (in shares) at Mar. 31, 2020	73,496,587
Beginning Balance at Dec. 31, 2019	$ 55	2,114,068	(44,865)	(2,243,515)	(174,257)
Beginning Balance (in shares) at Dec. 31, 2019	54,956,341
Foreign currency translation adjustments					(42)
Net unrealized gain (loss) on available-for-sale securities					(6)
Net loss					(191,579)
Ending Balance at Jun. 30, 2020	$ 88	2,382,544	(44,913)	(2,435,094)	(97,375)
Ending Balance (in shares) at Jun. 30, 2020	88,196,705
Beginning Balance at Mar. 31, 2020	$ 73	2,260,671	(44,890)	(2,342,847)	(126,993)
Beginning Balance (in shares) at Mar. 31, 2020	73,496,587
Exercise of stock options		(41)			(41)
Exercise of stock options (in shares)	6,661
Issuance of common stock from vesting of restricted stock units (in shares)	113,461
Issuance of common stock under employee stock purchase plan		907			907
Issuance of common stock under employee stock purchase plan (in shares)	158,126
Share-based compensation expense		13,313			13,313
Foreign currency translation adjustments			61		61
Net unrealized gain (loss) on available-for-sale securities			(84)		(84)
Issuance of common stock, net of issuance costs	$ 11	83,416			83,427
Issuance of common stock, net of issuance costs (in shares)	11,090,000
Convertible senior notes conversion	$ 4	24,278			24,282
Convertible senior notes conversion (in shares)	3,331,870
Net loss				(92,247)	(92,247)
Ending Balance at Jun. 30, 2020	$ 88	2,382,544	(44,913)	(2,435,094)	(97,375)
Ending Balance (in shares) at Jun. 30, 2020	88,196,705
Beginning Balance at Dec. 31, 2020	$ 104	2,498,179	(44,304)	(2,612,727)	$ (158,748)
Beginning Balance (in shares) at Dec. 31, 2020	103,699,109				103,699,109
Exercise of stock options		27			$ 27
Exercise of stock options (in shares)	5,609
Issuance of common stock from vesting of restricted stock units	$ 1	(1)
Issuance of common stock from vesting of restricted stock units (in shares)	853,239
Share-based compensation expense		4,039			4,039
Foreign currency translation adjustments			(80)		(80)
Net loss				(66,277)	(66,277)
Ending Balance at Mar. 31, 2021	$ 105	2,502,244	(44,384)	(2,679,004)	(221,039)
Ending Balance (in shares) at Mar. 31, 2021	104,557,957
Beginning Balance at Dec. 31, 2020	$ 104	2,498,179	(44,304)	(2,612,727)	$ (158,748)
Beginning Balance (in shares) at Dec. 31, 2020	103,699,109				103,699,109
Exercise of stock options (in shares)					7,087
Foreign currency translation adjustments					$ (66)
Net loss					(132,725)
Ending Balance at Jun. 30, 2021	$ 118	2,582,721	(44,370)	(2,745,452)	$ (206,983)
Ending Balance (in shares) at Jun. 30, 2021	118,403,984				118,403,984
Beginning Balance at Mar. 31, 2021	$ 105	2,502,244	(44,384)	(2,679,004)	$ (221,039)
Beginning Balance (in shares) at Mar. 31, 2021	104,557,957
Exercise of stock options		9			9
Exercise of stock options (in shares)	1,478
Issuance of common stock from vesting of restricted stock units (in shares)	193,936
Issuance of common stock under employee stock purchase plan		647			647
Issuance of common stock under employee stock purchase plan (in shares)	158,382
Share-based compensation expense		7,362			7,362
Foreign currency translation adjustments			14		14
Issuance of common stock, net of issuance costs	$ 13	72,459			72,472
Issuance of common stock, net of issuance costs (in shares)	13,492,231
Net loss				(66,448)	(66,448)
Ending Balance at Jun. 30, 2021	$ 118	$ 2,582,721	$ (44,370)	$ (2,745,452)	$ (206,983)
Ending Balance (in shares) at Jun. 30, 2021	118,403,984				118,403,984

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Operating activities
Net loss	$ (132,725)	$ (191,579)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense	11,401	26,274
Depreciation and amortization	4,478	4,128
Amortization of premiums and discounts on available-for-sale securities		(174)
Amortization of debt issuance costs	1,260	1,423
Write-off of debt issuance costs related to convertible senior notes transactions		4,344
Loss on convertible senior notes conversion		7,791
Loss on extinguishment of debt		3,277
Other	1,908
Changes in operating assets and liabilities:
Accounts receivable	2,331	2,359
Inventory	6,525	4,357
Prepaid and accrued research and development expenses	(1,736)	(5,328)
Other operating assets and liabilities	(3,963)	5,895
Accounts payable	(4,551)	(7,804)
Other accrued expenses	6,427	2,686
Net cash used in operating activities	(108,645)	(142,351)
Investing activities
Purchases of property and equipment	(154)	(75)
Purchases of available-for-sale securities		(9,962)
Sales of available-for-sale securities		144,644
Acquired in-process research and development - milestone payment		(8,000)
Net cash (used in) provided by investing activities	(154)	126,607
Financing activities
Proceeds from sale of common stock, net of issuance costs	72,472	246,727
Payment of convertible senior notes		(164,443)
Proceeds from borrowings under financing agreement	27,154	33,322
Proceeds from the exercise of stock options and employee stock purchases	683	868
Payments on finance leases	(780)	(720)
Payments on other long-term liabilities	(213)	(103)
Net cash provided by financing activities	99,316	115,651
Effect of exchange rate changes on cash and cash equivalents	(542)	(304)
(Decrease) increase in cash and cash equivalents	(10,025)	99,603
Cash and cash equivalents at beginning of period	240,229	161,833
Cash and cash equivalents at end of period	230,204	261,436
Supplemental disclosure of cash flow information:
Cash paid for interest	5,167	6,006
Non-cash investing and financing activities:
Vesting of restricted stock units	$ 8,274	$ 6,255

Nature of Business

Nature of Business	6 Months Ended
	Jun. 30, 2021
Nature of Business
Nature of Business	CLOVIS ONCOLOGY, INC. ​ NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS ​ 1. Nature of Business ​ Clovis Oncology, Inc. (together with its consolidated subsidiaries, the “Company”, “Clovis”, “we”, “our”, “us”) is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. We target our development programs for the treatment of specific subsets of cancer populations, and simultaneously develop, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. We have and intend to continue to license or acquire rights to oncology compounds in all stages of development. In exchange for the right to develop and commercialize these compounds, we generally expect to provide the licensor with a combination of upfront payments, milestone payments and royalties on future sales. In addition, we generally expect to assume the responsibility for future drug development and commercialization costs. We currently operate in two segments. Since inception, our operations have consisted primarily of developing in-licensed compounds, evaluating new product acquisition candidates and general corporate activities and since 2016 we have also marketed and sold products. ​ Our marketed product Rubraca® (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (“PARP”), is marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer and also an indication specific to metastatic castration-resistant prostate cancer (“mCRPC”). The initial indication received approval from the United States Food and Drug Administration (“FDA”) in December 2016 and covers the treatment of adult patients with deleterious BRCA ​ In May 2020, the FDA approved Rubraca for the treatment of adult patients with mCRPC associated with a deleterious BRCA BRCA ATM ​ In Europe, the European Commission granted a conditional marketing authorization in May 2018 for Rubraca as monotherapy treatment of adult patients with platinum-sensitive, relapsed or progressive, BRCA BRCA ​ In December 2020, Rubraca met the primary study endpoint of significantly improving PFS BRCA ​ Beyond our labeled indications, we have a clinical development program underway to further evaluate Rubraca in a variety of solid tumor types, either as monotherapy or in combination with other agents, including several studies as part of our ongoing clinical collaboration with Bristol Myers Squibb Company (“Bristol Myers Squibb”) to evaluate its immunotherapy OPDIVO® (nivolumab) in combination with Rubraca. We anticipate initial data of Rubraca monotherapy versus placebo from our ATHENA study in the first quarter of 2022, with results of the separate analysis of Rubraca in combination with Opdivo anticipated in the second half of 2022 based on protocol-defined assumptions. However, the actual timing of ATHENA data readouts is dependent on the occurrence of the protocol-specified number of progression events. The three anticipated data readouts, ATHENA monotherapy, ATHENA combination and TRITON3 discussed above, provide the potential to obtain approvals that reach larger patient populations in earlier lines of therapy for ovarian and prostate cancers, in which Rubraca is currently approved in later-line indications. ​ We initiated the Phase 2 LODESTAR study in December 2019 to evaluate Rubraca as monotherapy treatment in patients with recurrent solid tumors associated with a deleterious mutation in homologous recombination repair genes. Based on initial results from the ongoing study, we see encouraging evidence of activity in patients with a biallelic tumor mutation of BRCA BRCA ​ We hold worldwide rights to Rubraca. ​ Pursuant to our license and collaboration agreement with 3B Pharmaceuticals GmbH (“ investigational new drug application (“ ​ We hold U.S. and global rights to FAP-2286, excluding Europe (defined to include Russia, Turkey and Israel), where 3BP retains rights. We are also collaborating with 3BP on a discovery program directed to up to three additional, undisclosed targets for targeted radionuclide therapy, to which we would have global rights for any resulting product candidates. We may potentially file an additional IND, for a candidate from this discovery program, in the second half of 2022. ​ Lucitanib, our product candidate currently in clinical development, is an investigational, oral, potent angiogenesis inhibitor which inhibits vascular endothelial growth factor receptors 1 through 3 (“VEGFR1-3”), platelet-derived growth factor receptors alpha and beta (“PDGFR α/β”) and fibroblast growth factor receptors 1 through 3 (“FGFR1-3”). Lucitanib inhibits the same three pathways as Lenvima® (lenvatinib), which has received an FDA approval for use in endometrial cancer in combination with Keytruda® (pembrolizumab), a PD-1 inhibitor. This, together with preclinical data for lucitanib in combination with a PD-1 inhibitor that demonstrated enhanced anti-tumor activity compared to that of single agents, represent a scientific rationale for development of lucitanib in combination with a PD-1 inhibitor, and in February 2019, lucitanib was added to our clinical collaboration with Bristol Myers Squibb. ​ We hold the global (excluding China) development and commercialization rights for lucitanib. ​ Basis of Presentation ​ All financial information presented includes the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. ​ The unaudited financial statements of Clovis Oncology, Inc. included herein reflect all adjustments that, in the opinion of management, are necessary to fairly state our financial position, results of operations and cash flows for the periods presented herein. Interim results may not be indicative of the results that may be expected for the full year. Certain information and footnote disclosures normally included in audited financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto which are included in our Annual Report on Form 10-K for the year ended December 31, 2020 (“2020 Form 10-K”) for a broader discussion of our business and the opportunities and risks inherent in such business. ​ Use of Estimates ​ The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and revenue and related disclosures. On an ongoing basis, we evaluate our estimates, including estimates related to revenue deductions, intangible asset impairment, clinical trial accruals and share-based compensation expense. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. ​ Liquidity ​ We have incurred significant net losses since inception and have relied on our ability to fund our operations through debt and equity financings. We expect operating losses and negative cash flows to continue for the foreseeable future. As we continue to incur losses, transition to profitability is dependent upon achieving a level of revenue from Rubraca adequate to support our cost structure. We may never achieve profitability, and unless or until we do, we will continue to need to raise additional cash. ​ Based on current estimates, we believe that our cash, cash equivalents and liquidity available under our financing agreement related to our ATHENA trial, together with current estimates for revenues generated by sales of Rubraca, will allow us to fund our operating plan through at least the next 12 months. ​

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2021
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies ​ Recently Issued Accounting Standards ​ From time to time, the Financial Accounting Standards Board (“FASB”) or other standards-setting bodies issue new accounting pronouncements. Updates to the FASB Accounting Standards Codification (“ASC”) are communicated through the issuance of an Accounting Standards Update (“ASU”). ​ In August 2020, the FASB issued guidance that simplifies an issuer’s accounting for debt and equity instruments. The guidance is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early application is permitted. We plan to adopt this guidance on January 1, 2022. We will evaluate the impact this guidance may have on our consolidated financial statements and related disclosures as the adoption date approaches. ​ Revenue Recognition ​ We are currently approved to sell Rubraca in the United States and Europe markets. We distribute our product principally through a limited number of specialty distributor and specialty pharmacy providers, collectively, our customers. Our customers subsequently sell our products to patients and health care providers. Separately, we have arrangements with certain payors and other third parties that provide for government-mandated and privately-negotiated rebates, chargebacks and discounts. ​ Product Revenue ​ Revenue from product sales are recognized when the performance obligation is satisfied, which is when customers obtain control of our product at a point in time, typically upon delivery. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less. ​ Reserves for Variable Consideration Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from price concessions that include rebates, chargebacks, discounts, co-pay assistance, estimated product returns and other allowances that are offered within contracts between us and our customers, health care providers, payors and other indirect customers relating to the sales of our product. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable or a current liability. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. The amount of variable consideration which is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we adjust these estimates, which would affect product revenue and earnings in the period such variances become known. ​ Government Rebates ​ GPO and Payor Rebates. ​ Chargebacks ​ Discounts and Fees ​ Co-pay assistance Returns ​ Cost of Sales – Product ​ Product cost of sales consists primarily of materials, third-party manufacturing costs as well as freight and royalties owed to our licensing partners for Rubraca sales. ​ Cost of Sales – Intangible Asset Amortization ​ Cost of sales for intangible asset amortization consists of the amortization of capitalized milestone payments made to our licensing partners upon FDA approval of Rubraca. Milestone payments are amortized on a straight-line basis over the estimated remaining patent life of Rubraca. ​ Accounts Receivable ​ We provide an allowance for credit losses based on experience and specifically identified risks. Accounts receivable are charged off against the allowance when we determine that recovery is unlikely and we cease collection efforts. ​ Inventory ​ Inventories are stated at the lower of cost or estimated net realizable value, on a first-in, first-out (“FIFO”) basis. Inventories include active pharmaceutical ingredient (“API”), contract manufacturing costs and overhead allocations. We begin capitalizing incurred inventory related costs upon regulatory approval. Prior to regulatory approval, incurred costs for the manufacture of the drugs that could potentially be available to support the commercial launch of our products are recognized as research and development expense. ​ We regularly analyze our inventory levels for excess quantities and obsolescence (expiration), considering factors such as historical and anticipated future sales compared to quantities on hand and the remaining shelf-life of Rubraca. Rubraca finished goods have a shelf-life of four years from the date of manufacture. We expect to sell the finished goods prior to expiration. The API currently has a shelf-life of four years from the date of manufacture but can be retested at an immaterial cost with no expected reduction in potency, thereby extending its shelf-life as needed. We expect to consume substantially all of the API over a period of approximately six years based on our long-range sales projections of Rubraca. ​ We write down inventory that has become obsolete, inventory that has a cost basis in excess of its estimated realizable value and/or inventory in excess of expected sales requirements. Expired inventory would be disposed of and the related costs would be written off as cost of product revenue. Inventories that are not expected to be consumed within 12 months following the balance sheet date are classified as long-term inventories. Long-term inventories primarily consist of API. ​ API is currently produced by Lonza. As the API has undergone significant manufacturing specific to its intended purpose at the point it is purchased by us, we classify the API as work-in-process inventory. In addition, we currently manufacture Rubraca finished goods with a single third-party manufacturer. The disruption or termination of the supply of API or the disruption or termination of the manufacturing of our commercial products could have a material adverse effect on our business, financial position and results of operations. API that is written off due to damage and certain costs related to our dedicated production train at Lonza are included in Other Operating Expenses on the Consolidated Statements of Operations and Comprehensive Loss. ​ Inventory used in clinical trials is expensed as research and development expense when it has been identified for such use. ​ Segment Information ​ We have two operating and reportable segments, U.S. and ex-U.S., based on product revenue by geographic areas. We designated our reporting segments based on the internal reporting used by the Chief Operating Decision Maker (“CODM”), which is our Chief Executive Officer, for making decisions and assessing performance as the source of our reportable segments. The CODM allocates resources and assesses the performance of each operating segment based on product revenue by geographic areas. Accordingly, we view our business as two reportable operating segments to evaluate performance, allocate resources, set operational targets and forecast our future period financial results. ​ We manage our assets on a company basis, not by segments, as many of our assets are shared or commingled. Our CODM does not regularly review asset information by reportable segment. The majority of long-lived assets for both segments are located in the United States. ​ Research and Development Expense ​ Research and development costs are charged to expense as incurred and include, but are not limited to, salary and benefits, share-based compensation, clinical trial activities, drug development and manufacturing, companion diagnostic development and third-party service fees, including contract research organizations and investigative sites. ​ Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided to us by our vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred and are reflected on the Consolidated Balance Sheets as prepaid or accrued research and development expenses. ​ Our other significant accounting policies are described in Note 2, Summary of Significant Accounting Policies

Financial Instruments and Fair

Financial Instruments and Fair Value Measurements	6 Months Ended
	Jun. 30, 2021
Financial Instruments and Fair Value Measurements
Financial Instruments and Fair Value Measurements	3. Financial Instruments and Fair Value Measurements ​ Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (at exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The three levels of inputs that may be used to measure fair value include: ​ Level 1: Quoted prices in active markets for identical assets or liabilities. Our Level 1 assets consist of money market investments. We do not have Level 1 liabilities. ​ ​ Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. We do not have Level 2 assets or liabilities. ​ ​ Level 3: Unobservable inputs that are supported by little or no market activity. We do not have Level 3 assets or liabilities. ​ The following table identifies our assets and liabilities that were measured at fair value on a recurring basis (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance Level 1 Level 2 Level 3 June 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Money market ​ $ 132,928 ​ $ 132,928 ​ $ — ​ $ — ​ Total assets at fair value ​ $ 132,928 ​ $ 132,928 ​ $ — ​ $ — ​ December 31, 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Money market ​ $ 147,921 ​ $ 147,921 ​ $ — ​ $ — ​ Total assets at fair value ​ $ 147,921 ​ $ 147,921 ​ $ — ​ $ — ​ ​ There were no liabilities that were measured at fair value on a recurring basis as of June 30, 2021. ​ Financial instruments not recorded at fair value include our convertible senior notes. At June 30, 2021, the carrying amount of the 2021 Notes was $64.4 million, which represents the aggregate principal amount net of remaining debt issuance costs, and the fair value was $63.1 million. At June 30, 2021, the carrying amount of the 2024 Notes (2019 Issuance) was $84.2 million, which represents the aggregate principal amount net of remaining debt issuance costs, and the fair value was $90.3 million. At June 30, 2021, the carrying amount of the 2024 Notes (2020 Issuance) was $56.7 million, which represents the aggregate principal amount net of remaining debt issuance costs, and the fair value was $60.2 million. At June 30, 2021, the carrying amount of the 2025 Notes was $294.9 million, which represents the aggregate principal amount net of remaining debt issuance costs, and the fair value was $223.2 million. The fair value was determined using Level 2 inputs based on the indicative pricing published by certain investment banks or trading levels of the convertible senior notes, which are not listed on any securities exchange or quoted on an inter-dealer automated quotation system. See Note 9, Debt

Inventories

Inventories	6 Months Ended
	Jun. 30, 2021
Inventories
Inventories	4. Inventories ​ The following table presents inventories as of June 30, 2021 and December 31, 2020 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ 2021 2020 Work-in-process $ 94,138 $ 102,507 Finished goods, net ​ 34,901 ​ 32,330 Total inventories $ 129,039 $ 134,837 ​ At June 30, 2021, we had $25.0 million of current inventory and $104.0 million of long-term inventory.

Other Current Assets

Other Current Assets	6 Months Ended
	Jun. 30, 2021
Other Current Assets
Other Current Assets	​ 5. Other Current Assets ​ Other current assets were comprised of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ ​ 2021 2020 Prepaid insurance ​ $ 2,485 ​ $ 782 ​ Prepaid IT ​ ​ 553 ​ ​ 753 ​ Prepaid variable considerations ​ ​ 440 ​ ​ 1,191 ​ Prepaid expenses - other ​ 3,852 ​ 2,193 ​ Value-added tax ("VAT") receivable ​ ​ 3,545 ​ ​ 2,202 ​ Receivable - other ​ 2,101 ​ 1,884 ​ Other ​ 80 ​ 125 ​ Total ​ $ 13,056 ​ $ 9,130 ​ ​

Intangible Assets and Goodwill

Intangible Assets and Goodwill	6 Months Ended
	Jun. 30, 2021
Intangible Assets and Goodwill
Intangible Assets and Goodwill	6. Intangible Assets and Goodwill ​ Intangible assets related to capitalized milestones under license agreements consisted of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ ​ 2021 2020 Intangible asset - milestones ​ $ 79,850 ​ $ 79,850 Accumulated amortization ​ (16,793) ​ (14,107) Total intangible asset, net ​ $ 63,057 ​ $ 65,743 ​ ​ The estimated useful lives of these intangible assets are based on the estimated remaining patent life of Rubraca and extend through 2031 in Europe and 2035 in the U.S. ​ We recorded amortization expense of $1.3 million and $2.7 million related to capitalized milestone payments during the three and six months ended June 30, 2021, respectively. We recorded amortization expense of $1.3 million and $2.5 million related to capitalized milestone payments during the three and six months ended June 30, 2020, respectively. Amortization expense is included in cost of sales – intangible asset amortization on the Consolidated Statements of Operations and Comprehensive Loss. ​ Estimated future amortization expense associated with intangibles is expected to be as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ 2021 (remaining six months) ​ ​ ​ ​ $ 2,686 2022 ​ ​ ​ ​ ​ 5,371 2023 ​ ​ ​ ​ ​ 5,371 2024 ​ ​ ​ ​ ​ 5,371 2025 ​ ​ ​ ​ ​ 5,371 Thereafter ​ ​ ​ ​ ​ 38,887 ​ ​ ​ ​ ​ $ 63,057 ​

Other Accrued Expenses

Other Accrued Expenses	6 Months Ended
	Jun. 30, 2021
Other Accrued Expenses
Other Accrued Expenses	7. Other Accrued Expenses ​ Other accrued expenses were comprised of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ ​ 2021 2020 Accrued personnel costs ​ $ 12,058 ​ $ 18,334 ​ Accrued interest payable for convertible senior notes ​ 3,753 ​ 2,991 ​ Income tax payable ​ ​ 1,340 ​ ​ 907 ​ Accrued corporate legal fees and professional services ​ ​ 280 ​ ​ 459 ​ Accrued royalties ​ ​ 5,579 ​ ​ 6,617 ​ Accrued variable considerations ​ ​ 13,901 ​ ​ 11,701 ​ Accrued expenses - other ​ 6,499 ​ 4,199 ​ Total ​ $ 43,410 ​ $ 45,208 ​ ​

Leases

Leases	6 Months Ended
	Jun. 30, 2021
Leases
Leases	8. Leases ​ At the inception of an arrangement, we determine whether the arrangement is or contains a lease based on the unique facts and circumstances. Most leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. We elected not to recognize on the balance sheet leases with terms of one year or less. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, we utilize the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. ​ The components of a lease should be split into three categories: lease components (e.g. land, building, etc.), non-lease components (e.g. common area maintenance, maintenance, consumables, etc.) and non-components (e.g. property taxes, insurance, etc.). Then the fixed and in-substance fixed contract consideration (including any related to non-components) must be allocated based on fair values assigned to the lease components and non-lease components. ​ Our facilities operating leases have lease components, non-lease components and non-components, which we have separated because the non-lease components and non-components have variable lease payments and are excluded from the measurement of the lease liabilities. The lease component results in a right-of-use asset being recorded on the balance sheet and amortized as lease expense on a straight-line basis to the statements of operations. ​ We lease all of our office facilities in the U.S. and Europe. Leases with an initial term of 12 months or less are not recorded on the balance sheet; we recognize lease expense for these leases on a straight-line basis over the lease term. Most leases include one or more options to renew. The exercise of lease renewal options is at our sole discretion. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants. ​ Prior to June 30, 2021, we had a finance lease and operating lease for certain equipment at the dedicated production train at Lonza, our non-exclusive manufacturer of the Rubraca API. Pursuant to the terms of Amendment 2 discussed in Note 14, Commitments and Contingencies ​ The components of lease expense and related cash flows were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended June 30, ​ Three months ended June 30, ​ 2021 2020 Lease cost ​ ​ ​ ​ ​ ​ Finance lease cost: ​ ​ ​ ​ ​ ​ Amortization of right-of-use assets ​ $ 474 ​ $ 474 Interest on lease liabilities ​ 178 ​ 208 Operating lease cost ​ 1,280 ​ 998 Short-term lease cost ​ 80 ​ 116 Variable lease cost ​ ​ 640 ​ ​ 472 Total lease cost ​ $ 2,652 ​ $ 2,268 ​ ​ ​ ​ ​ ​ ​ Operating cash flows from finance leases ​ $ 178 ​ $ 208 Operating cash flows from operating leases ​ $ 1,280 ​ $ 998 Financing cash flows from finance leases ​ $ 394 ​ $ 364 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six months ended June 30, ​ Six months ended June 30, ​ 2021 2020 Lease cost ​ ​ ​ ​ ​ ​ Finance lease cost: ​ ​ ​ ​ ​ ​ Amortization of right-of-use assets ​ $ 947 ​ $ 947 Interest on lease liabilities ​ 363 ​ 423 Operating lease cost ​ 2,533 ​ 2,124 Short-term lease cost ​ 160 ​ 222 Variable lease cost ​ ​ 1,163 ​ ​ 1,070 Total lease cost ​ $ 5,166 ​ $ 4,786 ​ ​ ​ ​ ​ ​ ​ Operating cash flows from finance leases ​ $ 363 ​ $ 423 Operating cash flows from operating leases ​ $ 2,533 ​ $ 2,124 Financing cash flows from finance leases ​ $ 780 ​ $ 720 ​ The weighted-average remaining lease term and weighted-average discount rate were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 June 30, 2020 ​ Weighted-average remaining lease term (years) ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ 6.2 ​ ​ 7.0 ​ Finance leases ​ ​ N/A ​ ​ 5.5 ​ Weighted-average discount rate ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ 8% ​ ​ 8% ​ Finance leases ​ ​ N/A ​ ​ 8% ​ ​ Future minimum commitments due under these lease agreements as of June 30, 2021 are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating Leases ​ ​ 2021 (remaining six months) ​ 2,842 ​ 2022 ​ 5,249 ​ 2023 ​ 4,690 ​ 2024 ​ ​ 4,686 ​ ​ 2025 ​ ​ 4,843 ​ ​ Thereafter ​ 9,972 ​ Present value adjustment ​ ​ (7,126) ​ ​ Present value of lease payments ​ $ 25,156 ​ ​ ​

Debt

Debt	6 Months Ended
	Jun. 30, 2021
Long-term Debt
Long-term Debt	9. Debt ​ The following is a summary of our convertible senior notes at June 30, 2021 and December 31, 2020 (principal amount in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Principal Amount ​ Principal Amount ​ ​ ​ ​ ​ Conversion rate per $1,000 ​ ​ June 30, 2021 ​ December 31, 2020 ​ Interest Rate ​ Maturity Date ​ principal amount (shares) 2021 Notes ​ $ 64,418 ​ $ 64,418 ​ 2.50% ​ September 15, 2021 ​ 16.1616 2024 Notes (2019 Issuance) ​ 85,782 ​ 85,782 ​ 4.50% ​ August 1, 2024 ​ 137.2213 2024 Notes (2020 Issuance) ​ ​ 57,500 ​ ​ 57,500 ​ 4.50% ​ August 1, 2024 ​ 160.3334 2025 Notes ​ 300,000 ​ 300,000 ​ 1.25% ​ May 1, 2025 ​ 13.1278 Total ​ ​ 507,700 ​ ​ 507,700 ​ ​ ​ ​ ​ ​ Unamortized debt issuance costs ​ ​ (7,588) ​ ​ (8,656) ​ ​ ​ ​ ​ ​ Convertible senior notes ​ $ 500,112 ​ $ 499,044 ​ ​ ​ ​ ​ ​ ​ Our convertible senior notes are governed by the terms of their respective indentures between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee. Holders may convert all or any portion of the senior notes at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the holders will receive shares of our common stock at an initial conversion rate as noted above. The conversion rate is subject to adjustment upon the occurrence of certain events described in the indentures. ​ If we undergo a fundamental change, as defined in the indenture, prior to the maturity date of the senior notes, holders may require us to repurchase for cash all or any portion of the senior notes at a fundamental change repurchase price equal to 100% of the principal amount of the senior notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. ​ The senior notes rank senior in right of payment to any of our indebtedness that is expressly subordinated in right of payment to the senior notes; equal in right of payment to all of our liabilities that are not so subordinated; effectively junior in right of payment to any secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables) of our subsidiaries. ​ The debt issuance costs are presented as a deduction from the convertible senior notes on the Consolidated Balance Sheets and are amortized as interest expense over the expected life of the convertible senior notes using the effective interest method. ​ Sixth Street Financing Agreement ​ On May 1, 2019, we entered into a financing agreement (the “Financing Agreement”) with certain affiliates of Sixth Street Partners, LLC (“Sixth Street”) in which we plan to borrow from Sixth Street amounts required to reimburse our actual costs and expenses incurred during each fiscal quarter (limited to agreed budgeted amounts), as such expenses are incurred, related to the ATHENA clinical trial, in an aggregate amount of up to $175 million (the amount actually borrowed, the “Borrowed Amount”). ​ We incur borrowings under the Financing Agreement on a quarterly basis, beginning with such expenses incurred during the quarter ended March 31, 2019 and ending generally by September 30, 2022. We are obligated to repay on a quarterly basis, beginning by September 30, 2022 (the “Repayment Start Date”). Quarterly payments are generally 9.75% of the direct worldwide Rubraca net sales, capped at $8.5 million. Dates and amounts may be impacted by certain milestones achieved by our ATHENA clinical trial. The maximum amount required to be repaid under the Financing Agreement is two times the aggregate Borrowed Amount, which may be $350 million in the event we borrow the full $175 million under the Financing Agreement. See full details of the Financing Agreement in our 2020 Form 10-K. ​ Our obligations under the Financing Agreement are secured under a Pledge and Security agreement by a first priority security interest in all of our assets related to Rubraca, including intellectual property rights and a pledge of the equity of our wholly owned subsidiaries, Clovis Oncology UK Limited and Clovis Oncology Ireland Limited. In addition, the obligations are guaranteed by Clovis Oncology UK Limited and Clovis Oncology Ireland Limited, secured by a first priority security interest in all the assets of those subsidiaries. ​ For the six months ended June 30, 2021, we have recorded $147.4 million as a long-term liability on the Consolidated Balance Sheets and future quarterly draws will be recorded as a long-term liability on the Consolidated Balance Sheets. In connection with the transaction, we incurred $1.8 million of debt issuance costs. The debt issuance costs are presented as a deduction from the Sixth Street financing liability on the Consolidated Balance Sheets and are amortized as interest expense over the expected life of the Financing Agreement using the straight-line method. As of June 30, 2021, the balance of unamortized debt issuance costs was $1.4 million. ​ For the six months ended June 30, 2021, we used an effective interest rate of 14.6%, which is based on the estimate of remaining cash flows. For subsequent periods, we will use the prospective method whereby a new effective interest rate is determined based on the revised estimate of remaining cash flows. The new rate is the discount rate that equates the present value of the revised estimate of remaining cash flows with the carrying amount of the debt, and it will be used to recognize interest expense for the remaining periods. Under this method, the effective interest rate is not constant, and any change in expected cash flows is recognized prospectively as an adjustment to the effective yield. ​ The following table sets forth total interest expense recognized during the three and six months ended June 30, 2021 and 2020 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended June 30, ​ Six months ended June 30, ​ ​ 2021 2020 2021 2020 Interest on convertible notes ​ $ 2,952 ​ $ 2,811 ​ $ 5,929 ​ $ 5,994 ​ Amortization of debt issuance costs ​ 622 ​ 637 ​ 1,260 ​ 1,423 ​ Debt issuance cost derecognized related to convertible debt transactions ​ ​ — ​ ​ 789 ​ ​ — ​ ​ 4,344 ​ Interest on finance lease ​ ​ 178 ​ ​ 208 ​ ​ 363 ​ ​ 423 ​ Interest on borrowings under financing agreement ​ ​ 4,993 ​ ​ 2,264 ​ ​ 9,203 ​ ​ 4,055 ​ Other interest ​ ​ 25 ​ ​ 30 ​ ​ 52 ​ ​ 61 ​ Total interest expense ​ $ 8,770 ​ $ 6,739 ​ $ 16,807 ​ $ 16,300 ​ ​

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2021
Stockholders' Equity
Stockholders' Equity	10. Stockholders’ Equity ​ Common Stock ​ The holders of common stock are entitled to one vote per share on all matters to be voted upon by our stockholders. Subject to the preferences that may be applicable to any outstanding shares of preferred stock, the holders of common stock are entitled to receive ratably such dividends, if any, as may be declared by our Board of Directors. ​ On May 17, 2021, we entered into a distribution agreement (the “Distribution Agreement”) with J.P. Morgan Securities LLC and BofA Securities, Inc., as agents (the “Agents”), pursuant to which we may offer and sell, from time to time, through the Agents, shares of our common stock having an aggregate offering price of up to $75.0 million in transactions that are deemed to be “at the market” offerings as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended, including sales made by means of ordinary brokers’ transactions, including directly on the Nasdaq Global Select Market or into any other existing trading market for the Shares, or sales made to or through a market maker, in block transactions or by any other method permitted by law, including negotiated transactions. Sales may be made at market prices prevailing at the time of a sale or at prices related to prevailing market prices or at negotiated prices. During the period between May 18, 2021 and June 9, 2021, we sold an aggregate of 13,492,231 shares of our common stock under the Distribution Agreement resulting gross proceeds of $75.0 million and net proceeds to us of $72.5 million, after deducting commissions and offering expenses, effectively closing out sales we may make pursuant to the Distribution Agreement. We have used and intend to use the net proceeds of this offering for general corporate purposes, including funding of our development programs, sales and marketing expenses associated with Rubraca, repayment, repurchase or refinance of our debt obligations, payment of milestones pursuant to our license agreements, general and administrative expenses, acquisition or licensing of additional product candidates or businesses and working capital. ​ Accumulated Other Comprehensive Loss ​ Accumulated other comprehensive loss consists of changes in foreign currency translation adjustments, which includes changes in a subsidiary’s functional currency, and unrealized gains and losses on available-for-sale securities. ​ The changes in accumulated balances related to each component of other comprehensive income (loss) are summarized for the three months ended June 30, 2021 and 2020, as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Foreign Currency ​ Unrealized ​ Total Accumulated ​ ​ Translation Adjustments ​ (Losses) Gains ​ Other Comprehensive Loss ​ ​ 2021 ​ 2020 ​ 2021 ​ 2020 ​ 2021 ​ 2020 ​ Balance at April 1, ​ $ (44,245) ​ $ (44,835) ​ $ (139) ​ $ (55) ​ $ (44,384) ​ $ (44,890) ​ Other comprehensive income (loss) ​ ​ 14 ​ ​ 61 ​ ​ — ​ ​ (84) ​ ​ 14 ​ ​ (23) ​ Total before tax ​ ​ (44,231) ​ ​ (44,774) ​ ​ (139) ​ ​ (139) ​ ​ (44,370) ​ ​ (44,913) ​ Tax effect ​ — ​ ​ — ​ — ​ ​ — ​ — ​ ​ — ​ Balance at June 30, ​ $ (44,231) ​ $ (44,774) ​ $ (139) ​ $ (139) ​ $ (44,370) ​ $ (44,913) ​ ​ The changes in accumulated balances related to each component of other comprehensive income (loss) are summarized for the six months ended June 30, 2021 and 2020, as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Foreign Currency ​ Unrealized ​ Total Accumulated ​ ​ Translation Adjustments ​ (Losses) Gains ​ Other Comprehensive Loss ​ ​ 2021 ​ 2020 ​ 2021 ​ 2020 ​ 2021 ​ 2020 ​ Balance at January 1, ​ $ (44,165) ​ $ (44,732) ​ $ (139) ​ $ (133) ​ $ (44,304) ​ $ (44,865) ​ Other comprehensive (loss) income ​ ​ (66) ​ ​ (42) ​ ​ — ​ ​ (6) ​ ​ (66) ​ ​ (48) ​ Total before tax ​ ​ (44,231) ​ ​ (44,774) ​ ​ (139) ​ ​ (139) ​ ​ (44,370) ​ ​ (44,913) ​ Tax effect ​ — ​ ​ — ​ — ​ ​ — ​ — ​ ​ — ​ Balance at June 30, ​ $ (44,231) ​ $ (44,774) ​ $ (139) ​ $ (139) ​ $ (44,370) ​ $ (44,913) ​ ​ There were no reclassifications out of accumulated other comprehensive loss in each of the three and six months ended June 30, 2021 and 2020.

Share-Based Compensation

Share-Based Compensation	6 Months Ended
	Jun. 30, 2021
Share-Based Compensation
Share-Based Compensation	11. Share-Based Compensation ​ Share-based compensation expense for all equity-based programs, including stock options, restricted stock units and the employee stock purchase plan, for the three and six months ended June 30, 2021 and 2020 was recognized in the accompanying Consolidated Statements of Operations and Comprehensive Loss as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended June 30, ​ Six months ended June 30, ​ ​ 2021 2020 2021 2020 Research and development ​ $ 3,474 ​ $ 6,636 ​ $ 6,350 ​ $ 13,561 ​ ​ Selling, general and administrative ​ 3,888 ​ 6,677 ​ 5,051 ​ 12,713 ​ ​ Total share-based compensation expense ​ $ 7,362 ​ $ 13,313 ​ $ 11,401 ​ $ 26,274 ​ ​ ​ We did not recognize a tax benefit related to share-based compensation expense during the three and six months ended June 30, 2021 and 2020, as we maintain net operating loss carryforwards and have established a valuation allowance against the entire net deferred tax asset as of June 30, 2021. ​ Stock Options ​ The following table summarizes the activity relating to our options to purchase common stock for the six months ended June 30, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ Weighted ​ Average ​ Aggregate ​ ​ ​ ​ Average ​ Remaining ​ Intrinsic ​ ​ Number of ​ Exercise ​ Contractual ​ Value ​ ​ Options ​ Price ​ Term (Years) ​ (Thousands) Outstanding at December 31, 2020 ​ 6,502,169 ​ $ 37.78 ​ ​ Granted ​ 1,017,132 ​ ​ 6.11 ​ ​ Exercised ​ (7,087) ​ ​ 4.98 ​ ​ Forfeited ​ (316,917) ​ ​ 39.02 ​ ​ Outstanding at June 30, 2021 ​ 7,195,297 ​ $ 33.28 5.8 ​ $ 309 ​ Vested and expected to vest at June 30, 2021 ​ 7,007,820 ​ $ 33.93 5.7 ​ $ 277 ​ Vested and exercisable at June 30, 2021 ​ 5,440,479 ​ $ 40.40 4.8 ​ $ 84 ​ ​ The aggregate intrinsic value in the table above represents the pretax intrinsic value, based on our closing stock price of $5.80 as of June 30, 2021, which would have been received by the option holders had all option holders with in-the-money options exercised their options as of that date. ​ The following table summarizes information about our stock options as of and for the three and six months ended June 30, 2021 and 2020 (in thousands, except per share amounts): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended June 30, ​ Six months ended June 30, ​ ​ 2021 2020 2021 2020 Weighted-average grant date fair value per share ​ $ 4.72 ​ $ 5.06 ​ $ 4.85 ​ $ 5.87 ​ Intrinsic value of options exercised ​ $ 1 ​ $ 87 ​ $ 15 ​ $ 91 ​ Cash received from stock option exercises ​ $ 8 ​ $ 72 ​ $ 35 ​ $ 74 ​ ​ As of June 30, 2021, the unrecognized share-based compensation expense related to unvested options, adjusted for expected forfeitures, was $14.1 million and the estimated weighted-average remaining vesting period was 1.6 years. ​ Restricted Stock ​ The following table summarizes the activity relating to our unvested restricted stock units (“RSUs”) for the six months ended June 30, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average ​ ​ Number of ​ Grant Date ​ ​ Units ​ Fair Value Unvested at December 31, 2020 ​ 2,964,297 ​ $ 14.36 ​ Granted ​ 2,631,278 ​ 6.22 ​ Vested ​ (1,047,175) ​ 16.73 ​ Forfeited ​ (294,733) ​ 9.10 ​ Unvested at June 30, 2021 ​ 4,253,667 ​ $ 9.11 ​ Expected to vest after June 30, 2021 ​ 3,655,671 ​ $ 9.35 ​ ​ As of June 30, 2021, the unrecognized share-based compensation expense related to unvested RSUs, adjusted for expected forfeitures, was $35.3 million and the estimated weighted-average remaining vesting period was 2.3 years.

License Agreements

License Agreements	6 Months Ended
	Jun. 30, 2021
License Agreements
License Agreements	12. License Agreements ​ Rucaparib ​ In June 2011, we entered into a license agreement with Pfizer, Inc. (“Pfizer”) to obtain the exclusive global rights to develop and commercialize Rubraca. The exclusive rights are exclusive even as to Pfizer and include the right to grant sublicenses. Pursuant to the terms of the license agreement, we made a $7.0 million upfront payment to Pfizer and are required to make additional payments to Pfizer for the achievement of certain development and regulatory and sales milestones and royalties on sales as required by the license agreement. Prior to the FDA approval of Rubraca, we made milestone payments of $1.4 million, which were recognized as acquired in-process research and development expense. ​ During 2016 through 2020, we paid Pfizer a total of $82.5 million in milestone payments related to FDA and European Commission approvals received for Rubraca. These milestone payments were recognized as intangible assets and are amortized over the estimated remaining useful life of Rubraca. ​ We are obligated under the license agreement to use commercially reasonable efforts to develop and commercialize Rubraca and we are responsible for all ongoing development and commercialization costs for Rubraca. We are required to make regulatory milestone payments to Pfizer of up to an additional $8.0 million in aggregate if specified clinical study objectives and regulatory filings, acceptances and approvals are achieved. In addition, we are obligated to make sales milestone payments to Pfizer if specified annual sales targets for Rubraca are met, which relate to annual sales targets of $250.0 million and above, which, in the aggregate, could amount to total milestone payments of $170.0 million, and tiered royalty payments at a mid-teen percentage rate on net sales, with standard provisions for royalty offsets to the extent we need to obtain any rights from third parties to commercialize Rubraca. ​ The license agreement with Pfizer will remain in effect until the expiration of all of our royalty and sublicense revenue obligations to Pfizer, determined on a product-by-product and country-by-country basis, unless we elect to terminate the license agreement earlier. If we fail to meet our obligations under the agreement and are unable to cure such failure within specified time periods, Pfizer can terminate the agreement, resulting in a loss of our rights to Rubraca and an obligation to assign or license to Pfizer any intellectual property rights or other rights we may have in Rubraca, including our regulatory filings, regulatory approvals, patents and trademarks for Rubraca. ​ In April 2012, we entered into a license agreement with AstraZeneca to acquire exclusive rights associated with Rubraca under a family of patents and patent applications that claim methods of treating patients with PARP inhibitors in certain indications. The license enables the development and commercialization of Rubraca for the uses claimed by these patents. AstraZeneca also receives royalties on net sales of Rubraca. ​ FAP-2286 and the R adionuclide Therapy Development Program ​ In September 2019, we entered into a global license and collaboration agreement with 3BP to develop and commercialize a PTRT and imaging agent targeting FAP. The lead candidate, designated internally as FAP-2286, is being developed pursuant to a global development plan agreed to by the parties. We are responsible for the costs of all preclinical and clinical development activities described in the plan, including the costs for a limited number of 3BP full-time equivalents and external costs incurred during the preclinical development phase of the collaboration. Upon the signing of the license and collaboration agreement in September 2019, we made a $9.4 million upfront payment to 3BP, which we recognized as acquired in-process research and development expense. ​ Pursuant to the terms of the FAP agreement, we are required to make additional payments to 3BP for annual technology access fees and upon the achievement of certain development and regulatory milestone events (or on certain dates, whichever occur earlier). We are also obligated to pay 3BP single- to low-double-digit royalties on net sales of the FAP-targeted therapeutic product and imaging agent, based on the volume of annual net sales achieved. In addition, 3BP is entitled to receive 34% of any consideration, excluding royalties on the therapeutic product, pursuant to any sublicenses we may grant. ​ We are obligated under the license and collaboration agreement to use diligent efforts to develop FAP-2286 and commercialize a FAP-targeted therapeutic product and imaging agent, and we are responsible for all commercialization costs in our territory. The agreement with 3BP will remain in effect until the expiration of our royalty obligations to 3BP, determined on a product-by-product and country-by-country basis, unless we elect to terminate the agreement earlier. If we fail to meet our obligations under the agreement and are unable to cure such failure within specified time periods, 3BP can terminate the agreement, resulting in a loss of our rights. 3BP also has the right to terminate the agreement under certain circumstances in connection with our change of control in which the acquiring party retains a product competitive with the FAP-targeted therapeutic product or, in the event marketing authorization has not yet been obtained, does not agree to the then-current global development plan. ​ We submitted two INDs for FAP-2286 for use as imaging and treatment agents in December 2020 to support an initial Phase 1 study to determine the dose and tolerability of FAP-2286 as a therapeutic agent with expansion cohorts planned in multiple tumor types as part of a global development program. In April 2021, we made a milestone payment to 3BP under the license and collaboration agreement of $2.2 million as a result of the FDA’s acceptance of the IND for the treatment agent. ​ In February 2020, we finalized the terms of a drug discovery collaboration agreement with 3BP to identify up to three additional, undisclosed targets for peptide-targeted radionuclide therapy, to which we will obtain global rights for any resulting product candidates. We are responsible for the costs of all preclinical and clinical development activities conducted under the discovery program, including the costs for a limited number of 3BP full-time equivalents and external costs incurred during the discovery and preclinical development phase for each collaboration target. The discovery collaboration agreement was effective December 31, 2019, for which we incurred a $2.1 million technology access fee, which we accrued and recognized as a research and development expense. ​ Pursuant to the terms of the discovery collaboration agreement, we are required to make additional payments to 3BP for annual technology access fees and upon the achievement of certain development and regulatory milestone events (or on certain dates, whichever occur earlier). We are also obligated to pay 3BP a 6% royalty on net sales of License Products (as defined in the agreement), based on the volume of quarterly net sales achieved. ​ We are obligated under the discovery collaboration agreement to use diligent efforts to develop and commercialize the product candidates, if any, that result from the discovery program, and we are responsible for all clinical development and commercialization costs. The agreement with 3BP will remain in effect until the expiration of our royalty obligations to 3BP, determined on a product-by-product and country-by-country basis, unless we elect to terminate the agreement earlier. If we fail to meet our obligations under the agreement and are unable to cure such failure within specified time periods, 3BP can terminate the agreement, resulting in a loss of our rights. ​ Lucitanib ​ On November 19, 2013, we acquired all of the issued and outstanding capital stock of EOS pursuant to the terms set forth in that certain Stock Purchase Agreement, dated as of November 19, 2013 (the “Stock Purchase Agreement”), by and among the Company, EOS, its shareholders (the “Sellers”) and Sofinnova Capital V FCPR, acting in its capacity as the Sellers’ representative. Following the acquisition, EOS became a wholly-owned subsidiary of the Company. Under the terms of the Stock Purchase Agreement, in addition to the initial purchase price paid at the time of the closing of the acquisition and other license fees due to Advenchen described below, we will also be obligated to pay to the Sellers a milestone payment of $65.0 million upon obtaining the first NDA approval from the FDA with respect to lucitanib. ​ In October 2008, Ethical Oncology Science, S.p.A. (“EOS”) (now known as Clovis Oncology Italy S.r.l.) entered into an exclusive license agreement with Advenchen Laboratories LLC (“Advenchen”) to develop and commercialize lucitanib on a global basis, excluding China. We are obligated to pay Advenchen tiered royalties at percentage rates in the mid-single digits on net sales of lucitanib, based on the volume of annual net sales achieved. In addition, after giving effect to the first and second amendments to the license agreement, we are required to pay to Advenchen 25% of any consideration, excluding royalties, we receive from sublicensees, in lieu of the milestone obligations set forth in the agreement. We are obligated under the agreement to use commercially reasonable efforts to develop and commercialize at least one product containing lucitanib, and we are also responsible for all remaining development and commercialization costs for lucitanib. The license agreement with Advenchen will remain in effect until the expiration of all of our royalty obligations to Advenchen, determined on a product-by-product and country-by-country basis, unless we elect to terminate the agreement earlier. If we fail to meet our obligations under the agreement and are unable to cure such failure within specified time periods, Advenchen can terminate the agreement, resulting in a loss of our rights to lucitanib. ​

Net Loss Per Common Share

Net Loss Per Common Share	6 Months Ended
	Jun. 30, 2021
Net Loss Per Common Share
Net Loss Per Common Share	13. Net Loss Per Common Share ​ Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding using the treasury-stock method for the stock options and RSUs and the if-converted method for the convertible senior notes. As a result of our net losses for the periods presented, all potentially dilutive common share equivalents were considered anti-dilutive and were excluded from the computation of diluted net loss per share. ​ The shares outstanding at the end of the respective periods presented in the table below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ Three and six months ended June 30, ​ ​ 2021 2020 Common shares under stock incentive plans ​ 4,524 ​ 4,156 ​ Convertible senior notes ​ 25,969 ​ 25,648 ​ Total potential dilutive shares ​ 30,493 ​ 29,804 ​ ​

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies
Commitments and Contingencies	14. Commitments and Contingencies ​ Royalty and License Fee Commitments ​ We have entered into certain license agreements, as identified in Note 12, License Agreements ​ Manufacture and Services Agreement Commitments ​ On October 3, 2016, we entered into a Manufacturing and Services Agreement (the “Agreement”) with a non-exclusive third-party supplier for the production of the active ingredient for Rubraca. Under the terms of the Agreement, we will provide the third-party supplier a rolling forecast for the supply of the active ingredient in Rubraca that will be updated by us on a quarterly basis. We are obligated to order material sufficient to satisfy an initial quantity specified in a forecast. In addition, the third-party supplier has constructed, in its existing facility, a production train that will be exclusively dedicated to the manufacture of the Rubraca active ingredient. We made scheduled capital program fee payments toward capital equipment and other costs associated with the construction of the dedicated production train. Beginning in the fourth quarter of 2018, once the facility was operational, we were obligated to pay a fixed facility fee each quarter for the duration of the Agreement, which expires on December 31, 2025, unless extended by mutual consent of the parties. As of June 30, 2021, $49.4 million of purchase commitments remain under the Agreement. ​ At the time we entered into the Agreement, we evaluated the Agreement as a whole and bifurcated into lease and non-lease components, which consisted of an operating lease of warehouse space, financial lease of equipment, purchase of leasehold improvements and prepaid manufacturing costs based upon the relative fair values of each of the deliverables. During October 2018, the production train was placed into service and we recorded the various components of the Agreement. ​ On June 16, 2021, we entered into amendment no. 2 of the Agreement with Lonza (“Amendment 2”). Pursuant to the terms of Amendment 2, we are paying Lonza $1.1 million to repurpose the production train so that Lonza will be able to use the facility to manufacture other products for third parties in addition to API for Clovis. Lonza is guaranteeing a minimum percentage usage of this production train for third parties and Lonza would reduce our fixed facility fee starting in 2023 based on this minimum percentage usage. If Lonza is able to utilize greater than the minimum guaranteed percentage, it will increase the reduction to our fixed facility fee. We evaluated Amendment 2 and determined that we no longer have a lease with Lonza at June 30, 2021 because Amendment 2 modified the terms of the Agreement in that Lonza will use a portion of the production train for third parties. The Agreement no longer conveys the right to direct the use of the identified asset and Clovis no longer has the right to obtain substantially all the economic benefit from the asset. As a result, the arrangement is no longer in scope of ​ Legal Proceedings ​ We and certain of our officers were named as defendants in several lawsuits, as described below. We cannot reasonably predict the outcome of these legal proceedings, nor can we estimate the amount of loss or range of loss, if any, that may result. An adverse outcome in these proceedings could have a material adverse effect on our results of operations, cash flows or financial condition. ​ Rociletinib-Related Litigation ​ In March 2017, two putative shareholders of the Company, Macalinao and McKenry (“ Plaintiffs”), filed shareholder derivative complaints against certain directors and officers of the Company in the Court of Chancery of the State of Delaware. On May 4, 2017, the Macalinao and McKenry actions were consolidated for all purposes in a single proceeding under the caption In re Clovis Oncology, Inc. Derivative Litigation, Case No, 2017-0222 (the “Consolidated Derivative Action”). On May 18, 2017, Plaintiffs filed a Consolidated Verified Shareholder Derivative Complaint (the “Consolidated Derivative Complaint”). The Consolidated Derivative Complaint generally alleged that the defendants breached their fiduciary duties owed to the Company by allegedly causing or allowing misrepresentations of the Company’s business operations and prospects, failing to ensure that the TIGER-X clinical trial for rociletinib was being conducted in accordance with applicable rules, regulations and protocols, and engaging in insider trading. The Consolidated Derivative Complaint sought, among other things, an award of money damages. On July 31, 2017, the defendants filed a motion to dismiss the Consolidated Derivative Complaint. Plaintiffs filed an opposition to the motion to dismiss on August 31, 2017, and the defendants filed a reply in further support of the motion to dismiss on September 26, 2017. ​ While the motion to dismiss remained pending, on November 19, 2018, Plaintiffs filed a motion for leave to file a supplemental consolidated complaint, and on November 20, 2018, the Court granted that motion. On November 27, 2018, Plaintiffs filed their supplemental complaint (the “Supplemental Derivative Complaint”), which adds allegations concerning the Company’s, Mr. Mahaffy’s and Mr. Mast’s settlements with the United States Securities and Exchange Commission. Pursuant to a briefing schedule entered by the Court, the defendants filed a supplemental motion to dismiss the Supplemental Derivative Complaint on February 6, 2019; Plaintiffs filed an opposition brief on February 22, 2019; and the defendants filed a reply brief on March 5, 2019. The Court held oral arguments on the defendants’ motions to dismiss on June 19, 2019. At the oral arguments, the Court ordered the parties to submit supplemental letter briefs on the motion to dismiss. On October 1, 2019, Vice Chancellor Joseph R. Slights III of the Delaware Chancery Court, issued a Memorandum Opinion granting in part and denying in part defendants’ motions to dismiss. The Supplemental Derivative Complaint was dismissed as to Plaintiffs’ derivative claims for unjust enrichment and insider trading. The Court allowed Plaintiffs’ remaining derivative claim for breach of fiduciary duty to proceed. Defendants filed an answer to the Supplemental Derivative Complaint on December 27, 2019. ​ On December 17, 2019, the parties participated in a mediation, which did not result in a settlement. On December 22, 2019, the Company’s Board of Directors formed a Special Litigation Committee (the “SLC”) to conduct an investigation of the claims asserted in the Supplemental Derivative Complaint. On February 18, 2020, the SLC moved to stay all proceedings in the Consolidated Derivative Action pending completion of its investigation. Plaintiffs filed their opposition to the motion to stay on March 3, 2020 and the SLC filed its reply on March 13, 2020. On May 12, 2020, after hearing oral argument, Vice Chancellor Slights granted the SLC’s motion to stay proceedings until September 18, 2020 so that the SLC may complete its investigation. On September 11, 2020, Vice Chancellor Slights granted the parties’ request to extend the stay until October 31, 2020, to allow the SLC further time to complete its investigation. On October 26, 2020, Vice Chancellor Slights granted the parties’ request to further extend the stay until November 15, 2020. On November 13, 2020, Vice Chancellor Slights granted the parties’ request to further extend the stay until December 15, 2020. ​ On December 16, 2020, the SLC filed a report (the “SLC Report”) containing the findings of its investigation. The SLC Report concludes that the claims asserted in the Consolidated Derivative Action lack merit. Specifically, the SLC Report finds that the defendants did not breach their fiduciary duties in connection with the Company’s TIGER-X clinical trial. Accordingly, on the same date that the SLC Report was filed, the SLC filed a motion to terminate the Consolidated Derivative Action in Delaware Chancery Court. A briefing schedule on the motion to terminate has not yet been set. ​ On March 26, 2021, in response to discovery requests from Plaintiffs, the SLC filed a motion for a protective order seeking to preclude discovery into the merits of the claims investigated by the SLC. On March 29, 2021, the Company joined the SLC’s motion for a protective order. Pursuant to a scheduling stipulation entered by the Court on April 5, 2021, Plaintiffs filed an opposition to the motion for a protective order on April 16, 2021, and the SLC filed its reply on April 30, 2021. Oral argument on the SLC’s motion for a protective order, originally scheduled for May 24, 2021, will occur on August 23, 2021. ​ While the motion to terminate the action remains pending before Vice Chancellor Slights, the Company does not believe this litigation will have a material impact on its financial position or results of operations. ​ European Patent Opposition ​ Two European patents in the rucaparib camsylate salt/polymorph patent family (European Patent 2534153 and its divisional European Patent 3150610) were opposed. In particular, opposition notices against European Patent 2534153 were filed by two parties on June 20, 2017. During an oral hearing that took place on December 4, 2018, the European Patent Office’s Opposition Division maintained European Patent 2534153 in amended and narrowed form with claims to certain crystalline forms of rucaparib camsylate, including, but not limited to, rucaparib S-camsylate Form A, the crystalline form in Rubraca. Clovis and one opponent, Hexal AG, appealed the written decision of the European Opposition Division and filed reply appeal briefs in early November 2019. An opposition against European Patent 3150610 was filed by Generics (UK) Limited on April 30, 2020 on grounds similar to those raised in the opposition notices against European Patent 2534153, which grounds are common in such proceedings. Moreover, these grounds of opposition, as well as documents based on which lack of patentability has been alleged, were considered by the European Patent Office during the examination stage, and the claims were deemed to comply with the applicable law when granting the patent. Clovis responded to the opposition notice in European Patent 3150610 on January 8, 2021, amending the claims to be directed to the use of rucaparib maleate in a method of inhibiting PARP activity or treating cancer. A preliminary opinion and summons to oral proceedings were issued on January 26, 2021. The oral hearing is scheduled for November 18, 2021. The preliminary opinion provides a non-binding indication of the Opposition Division’s initial view based on the documents that have thus far been submitted, which agrees with our positions on a number of grounds of opposition and agrees with an objection made by the opponent, but only with respect to some of the claims. As part of the opposition proceedings, we have the opportunity to submit further arguments and pursue alternative claims in the form of auxiliary requests. While the ultimate results of patent challenges can be difficult to predict, it is our view that a number of factors support patentability, and we believe a successful challenge of all claims would be difficult.

Segment Information

Segment Information	6 Months Ended
	Jun. 30, 2021
Segment Information
Segment Information	15. Segment Information ​ The following table presents information about our reportable segments for the three months ended June 30, 2021 and 2020 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended June 30, ​ 2021 ​ 2020 ​ ​ U.S. Ex-U.S. Total U.S. Ex-U.S. Total Product revenue ​ $ 27,680 ​ $ 9,140 ​ $ 36,820 ​ $ 36,719 ​ $ 3,168 ​ $ 39,887 ​ Operating expenses: ​ ​ ​ ​ ​ ​ ​ Cost of sales - product ​ 5,402 ​ 2,892 ​ 8,294 ​ 7,522 ​ 1,598 ​ 9,120 ​ Cost of sales - intangible asset amortization ​ 620 ​ 723 ​ 1,343 ​ 557 ​ 723 ​ 1,280 ​ Research and development ​ 43,774 ​ 1,985 ​ 45,759 ​ 67,862 ​ 2,016 ​ 69,878 ​ Selling, general and administrative ​ 26,351 ​ 6,567 ​ 32,918 ​ 35,969 ​ 5,933 ​ 41,902 ​ Acquired in-process research and development ​ ​ 2,204 ​ ​ — ​ ​ 2,204 ​ ​ — ​ ​ — ​ ​ — ​ Other operating expenses ​ ​ 3,884 ​ ​ — ​ ​ 3,884 ​ ​ 355 ​ ​ — ​ ​ 355 ​ Total expenses ​ 82,235 12,167 94,402 112,265 10,270 122,535 Operating loss ​ $ (54,555) ​ $ (3,027) ​ ​ (57,582) ​ $ (75,546) ​ $ (7,102) ​ ​ (82,648) ​ Other income (expense): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Interest expense ​ ​ ​ ​ ​ ​ ​ ​ (8,770) ​ ​ ​ ​ ​ ​ ​ ​ (6,739) ​ Foreign currency (loss) gain ​ ​ ​ ​ ​ ​ ​ ​ (206) ​ ​ ​ ​ ​ ​ ​ ​ 142 ​ Loss on extinguishment of debt ​ ​ ​ ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ ​ ​ ​ (3,277) ​ Other income ​ ​ ​ ​ ​ ​ ​ ​ 107 ​ ​ ​ ​ ​ ​ ​ ​ 239 ​ Other income (expense), net ​ ​ ​ ​ ​ ​ ​ ​ (8,869) ​ ​ ​ ​ ​ ​ ​ ​ (9,635) ​ Loss before income taxes ​ ​ ​ ​ ​ ​ ​ ​ (66,451) ​ ​ ​ ​ ​ ​ ​ ​ (92,283) ​ Income tax benefit ​ ​ ​ ​ ​ ​ ​ ​ 3 ​ ​ ​ ​ ​ ​ ​ ​ 36 ​ Net loss ​ ​ ​ ​ ​ ​ ​ $ (66,448) ​ ​ ​ ​ ​ ​ ​ $ (92,247) ​ ​ The following table presents information about our reportable segments for the six months ended June 30, 2021 and 2020 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six months ended June 30, ​ 2021 ​ 2020 ​ ​ U.S. Ex-U.S. Total U.S. Ex-U.S. Total Product revenue ​ $ 59,381 ​ $ 15,492 ​ $ 74,873 ​ $ 76,022 ​ $ 6,429 ​ $ 82,451 ​ Operating expenses: ​ ​ ​ ​ ​ ​ ​ Cost of sales - product ​ 11,560 ​ 5,002 ​ 16,562 ​ 15,577 ​ 2,639 ​ 18,216 ​ Cost of sales - intangible asset amortization ​ 1,241 ​ 1,445 ​ 2,686 ​ 1,047 ​ 1,445 ​ 2,492 ​ Research and development ​ 94,604 ​ 3,960 ​ 98,564 ​ 134,149 ​ 3,950 ​ 138,099 ​ Selling, general and administrative ​ 50,672 ​ 12,187 ​ 62,859 ​ 72,124 ​ 12,376 ​ 84,500 ​ Acquired in-process research and development ​ ​ 2,204 ​ ​ — ​ ​ 2,204 ​ ​ — ​ ​ — ​ ​ — ​ Other operating expenses ​ ​ 7,591 ​ ​ — ​ ​ 7,591 ​ ​ 3,805 ​ ​ — ​ ​ 3,805 ​ Total expenses ​ 167,872 22,594 190,466 226,702 20,410 247,112 Operating loss ​ $ (108,491) ​ $ (7,102) ​ ​ (115,593) ​ $ (150,680) ​ $ (13,981) ​ ​ (164,661) ​ Other income (expense): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Interest expense ​ ​ ​ ​ ​ ​ ​ ​ (16,807) ​ ​ ​ ​ ​ ​ ​ ​ (16,300) ​ Foreign currency loss ​ ​ ​ ​ ​ ​ ​ ​ (752) ​ ​ ​ ​ ​ ​ ​ ​ (735) ​ Loss on convertible senior notes conversion ​ ​ ​ ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ ​ ​ ​ (7,791) ​ Loss on extinguishment of debt ​ ​ ​ ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ ​ ​ ​ (3,277) ​ Other income ​ ​ ​ ​ ​ ​ ​ ​ 290 ​ ​ ​ ​ ​ ​ ​ ​ 1,081 ​ Other income (expense), net ​ ​ ​ ​ ​ ​ ​ ​ (17,269) ​ ​ ​ ​ ​ ​ ​ ​ (27,022) ​ Loss before income taxes ​ ​ ​ ​ ​ ​ ​ ​ (132,862) ​ ​ ​ ​ ​ ​ ​ ​ (191,683) ​ Income tax benefit ​ ​ ​ ​ ​ ​ ​ ​ 137 ​ ​ ​ ​ ​ ​ ​ ​ 104 ​ Net loss ​ ​ ​ ​ ​ ​ ​ $ (132,725) ​ ​ ​ ​ ​ ​ ​ $ (191,579) ​ ​

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
Summary of Significant Accounting Policies
Basis of Presentation	Basis of Presentation ​ All financial information presented includes the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. ​ The unaudited financial statements of Clovis Oncology, Inc. included herein reflect all adjustments that, in the opinion of management, are necessary to fairly state our financial position, results of operations and cash flows for the periods presented herein. Interim results may not be indicative of the results that may be expected for the full year. Certain information and footnote disclosures normally included in audited financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto which are included in our Annual Report on Form 10-K for the year ended December 31, 2020 (“2020 Form 10-K”) for a broader discussion of our business and the opportunities and risks inherent in such business. ​
Use of Estimates	Use of Estimates ​ The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and revenue and related disclosures. On an ongoing basis, we evaluate our estimates, including estimates related to revenue deductions, intangible asset impairment, clinical trial accruals and share-based compensation expense. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. ​
Liquidity	Liquidity ​ We have incurred significant net losses since inception and have relied on our ability to fund our operations through debt and equity financings. We expect operating losses and negative cash flows to continue for the foreseeable future. As we continue to incur losses, transition to profitability is dependent upon achieving a level of revenue from Rubraca adequate to support our cost structure. We may never achieve profitability, and unless or until we do, we will continue to need to raise additional cash. ​ Based on current estimates, we believe that our cash, cash equivalents and liquidity available under our financing agreement related to our ATHENA trial, together with current estimates for revenues generated by sales of Rubraca, will allow us to fund our operating plan through at least the next 12 months.
Recently Issued Accounting Standards	Recently Issued Accounting Standards ​ From time to time, the Financial Accounting Standards Board (“FASB”) or other standards-setting bodies issue new accounting pronouncements. Updates to the FASB Accounting Standards Codification (“ASC”) are communicated through the issuance of an Accounting Standards Update (“ASU”). ​ In August 2020, the FASB issued guidance that simplifies an issuer’s accounting for debt and equity instruments. The guidance is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early application is permitted. We plan to adopt this guidance on January 1, 2022. We will evaluate the impact this guidance may have on our consolidated financial statements and related disclosures as the adoption date approaches. ​
Revenue Recognition	Revenue Recognition ​ We are currently approved to sell Rubraca in the United States and Europe markets. We distribute our product principally through a limited number of specialty distributor and specialty pharmacy providers, collectively, our customers. Our customers subsequently sell our products to patients and health care providers. Separately, we have arrangements with certain payors and other third parties that provide for government-mandated and privately-negotiated rebates, chargebacks and discounts. ​ Product Revenue ​ Revenue from product sales are recognized when the performance obligation is satisfied, which is when customers obtain control of our product at a point in time, typically upon delivery. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less. ​ Reserves for Variable Consideration Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from price concessions that include rebates, chargebacks, discounts, co-pay assistance, estimated product returns and other allowances that are offered within contracts between us and our customers, health care providers, payors and other indirect customers relating to the sales of our product. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable or a current liability. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. The amount of variable consideration which is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we adjust these estimates, which would affect product revenue and earnings in the period such variances become known. ​ Government Rebates ​ GPO and Payor Rebates. ​ Chargebacks ​ Discounts and Fees ​ Co-pay assistance Returns ​
Cost of Sales	Cost of Sales – Product ​ Product cost of sales consists primarily of materials, third-party manufacturing costs as well as freight and royalties owed to our licensing partners for Rubraca sales. ​ Cost of Sales – Intangible Asset Amortization ​ Cost of sales for intangible asset amortization consists of the amortization of capitalized milestone payments made to our licensing partners upon FDA approval of Rubraca. Milestone payments are amortized on a straight-line basis over the estimated remaining patent life of Rubraca.
Accounts Receivable	Accounts Receivable ​ We provide an allowance for credit losses based on experience and specifically identified risks. Accounts receivable are charged off against the allowance when we determine that recovery is unlikely and we cease collection efforts.
Inventory	Inventory ​ Inventories are stated at the lower of cost or estimated net realizable value, on a first-in, first-out (“FIFO”) basis. Inventories include active pharmaceutical ingredient (“API”), contract manufacturing costs and overhead allocations. We begin capitalizing incurred inventory related costs upon regulatory approval. Prior to regulatory approval, incurred costs for the manufacture of the drugs that could potentially be available to support the commercial launch of our products are recognized as research and development expense. ​ We regularly analyze our inventory levels for excess quantities and obsolescence (expiration), considering factors such as historical and anticipated future sales compared to quantities on hand and the remaining shelf-life of Rubraca. Rubraca finished goods have a shelf-life of four years from the date of manufacture. We expect to sell the finished goods prior to expiration. The API currently has a shelf-life of four years from the date of manufacture but can be retested at an immaterial cost with no expected reduction in potency, thereby extending its shelf-life as needed. We expect to consume substantially all of the API over a period of approximately six years based on our long-range sales projections of Rubraca. ​ We write down inventory that has become obsolete, inventory that has a cost basis in excess of its estimated realizable value and/or inventory in excess of expected sales requirements. Expired inventory would be disposed of and the related costs would be written off as cost of product revenue. Inventories that are not expected to be consumed within 12 months following the balance sheet date are classified as long-term inventories. Long-term inventories primarily consist of API. ​ API is currently produced by Lonza. As the API has undergone significant manufacturing specific to its intended purpose at the point it is purchased by us, we classify the API as work-in-process inventory. In addition, we currently manufacture Rubraca finished goods with a single third-party manufacturer. The disruption or termination of the supply of API or the disruption or termination of the manufacturing of our commercial products could have a material adverse effect on our business, financial position and results of operations. API that is written off due to damage and certain costs related to our dedicated production train at Lonza are included in Other Operating Expenses on the Consolidated Statements of Operations and Comprehensive Loss. ​ Inventory used in clinical trials is expensed as research and development expense when it has been identified for such use.
Segment Information	Segment Information ​ We have two operating and reportable segments, U.S. and ex-U.S., based on product revenue by geographic areas. We designated our reporting segments based on the internal reporting used by the Chief Operating Decision Maker (“CODM”), which is our Chief Executive Officer, for making decisions and assessing performance as the source of our reportable segments. The CODM allocates resources and assesses the performance of each operating segment based on product revenue by geographic areas. Accordingly, we view our business as two reportable operating segments to evaluate performance, allocate resources, set operational targets and forecast our future period financial results. ​ We manage our assets on a company basis, not by segments, as many of our assets are shared or commingled. Our CODM does not regularly review asset information by reportable segment. The majority of long-lived assets for both segments are located in the United States.
Research and Development Expense	Research and Development Expense ​ Research and development costs are charged to expense as incurred and include, but are not limited to, salary and benefits, share-based compensation, clinical trial activities, drug development and manufacturing, companion diagnostic development and third-party service fees, including contract research organizations and investigative sites. ​ Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided to us by our vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred and are reflected on the Consolidated Balance Sheets as prepaid or accrued research and development expenses. ​ Our other significant accounting policies are described in Note 2, Summary of Significant Accounting Policies
Net Loss Per Common Share	Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding using the treasury-stock method for the stock options and RSUs and the if-converted method for the convertible senior notes. As a result of our net losses for the periods presented, all potentially dilutive common share equivalents were considered anti-dilutive and were excluded from the computation of diluted net loss per share.

Financial Instruments and Fai_2

Financial Instruments and Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2021
Financial Instruments and Fair Value Measurements
Assets Measured at Fair Value on Recurring Basis	The following table identifies our assets and liabilities that were measured at fair value on a recurring basis (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance Level 1 Level 2 Level 3 June 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Money market ​ $ 132,928 ​ $ 132,928 ​ $ — ​ $ — ​ Total assets at fair value ​ $ 132,928 ​ $ 132,928 ​ $ — ​ $ — ​ December 31, 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Money market ​ $ 147,921 ​ $ 147,921 ​ $ — ​ $ — ​ Total assets at fair value ​ $ 147,921 ​ $ 147,921 ​ $ — ​ $ — ​

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2021
Inventories
Schedule of Inventories	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ 2021 2020 Work-in-process $ 94,138 $ 102,507 Finished goods, net ​ 34,901 ​ 32,330 Total inventories $ 129,039 $ 134,837

Other Current Assets (Tables)

Other Current Assets (Tables)	6 Months Ended
	Jun. 30, 2021
Other Current Assets
Schedule Of other current assets	Other current assets were comprised of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ ​ 2021 2020 Prepaid insurance ​ $ 2,485 ​ $ 782 ​ Prepaid IT ​ ​ 553 ​ ​ 753 ​ Prepaid variable considerations ​ ​ 440 ​ ​ 1,191 ​ Prepaid expenses - other ​ 3,852 ​ 2,193 ​ Value-added tax ("VAT") receivable ​ ​ 3,545 ​ ​ 2,202 ​ Receivable - other ​ 2,101 ​ 1,884 ​ Other ​ 80 ​ 125 ​ Total ​ $ 13,056 ​ $ 9,130 ​

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	6 Months Ended
	Jun. 30, 2021
Intangible Assets and Goodwill
Intangible assets related to capitalized milestones under license agreements	Intangible assets related to capitalized milestones under license agreements consisted of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ ​ 2021 2020 Intangible asset - milestones ​ $ 79,850 ​ $ 79,850 Accumulated amortization ​ (16,793) ​ (14,107) Total intangible asset, net ​ $ 63,057 ​ $ 65,743
Estimated future amortization expense for intangible assets	Estimated future amortization expense associated with intangibles is expected to be as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ 2021 (remaining six months) ​ ​ ​ ​ $ 2,686 2022 ​ ​ ​ ​ ​ 5,371 2023 ​ ​ ​ ​ ​ 5,371 2024 ​ ​ ​ ​ ​ 5,371 2025 ​ ​ ​ ​ ​ 5,371 Thereafter ​ ​ ​ ​ ​ 38,887 ​ ​ ​ ​ ​ $ 63,057

Other Accrued Expenses (Tables)

Other Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2021
Other Accrued Expenses
Schedule of other accrued expenses	Other accrued expenses were comprised of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ ​ 2021 2020 Accrued personnel costs ​ $ 12,058 ​ $ 18,334 ​ Accrued interest payable for convertible senior notes ​ 3,753 ​ 2,991 ​ Income tax payable ​ ​ 1,340 ​ ​ 907 ​ Accrued corporate legal fees and professional services ​ ​ 280 ​ ​ 459 ​ Accrued royalties ​ ​ 5,579 ​ ​ 6,617 ​ Accrued variable considerations ​ ​ 13,901 ​ ​ 11,701 ​ Accrued expenses - other ​ 6,499 ​ 4,199 ​ Total ​ $ 43,410 ​ $ 45,208 ​

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2021
Leases
Schedule of components of lease expense and related cash flows	The components of lease expense and related cash flows were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended June 30, ​ Three months ended June 30, ​ 2021 2020 Lease cost ​ ​ ​ ​ ​ ​ Finance lease cost: ​ ​ ​ ​ ​ ​ Amortization of right-of-use assets ​ $ 474 ​ $ 474 Interest on lease liabilities ​ 178 ​ 208 Operating lease cost ​ 1,280 ​ 998 Short-term lease cost ​ 80 ​ 116 Variable lease cost ​ ​ 640 ​ ​ 472 Total lease cost ​ $ 2,652 ​ $ 2,268 ​ ​ ​ ​ ​ ​ ​ Operating cash flows from finance leases ​ $ 178 ​ $ 208 Operating cash flows from operating leases ​ $ 1,280 ​ $ 998 Financing cash flows from finance leases ​ $ 394 ​ $ 364 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six months ended June 30, ​ Six months ended June 30, ​ 2021 2020 Lease cost ​ ​ ​ ​ ​ ​ Finance lease cost: ​ ​ ​ ​ ​ ​ Amortization of right-of-use assets ​ $ 947 ​ $ 947 Interest on lease liabilities ​ 363 ​ 423 Operating lease cost ​ 2,533 ​ 2,124 Short-term lease cost ​ 160 ​ 222 Variable lease cost ​ ​ 1,163 ​ ​ 1,070 Total lease cost ​ $ 5,166 ​ $ 4,786 ​ ​ ​ ​ ​ ​ ​ Operating cash flows from finance leases ​ $ 363 ​ $ 423 Operating cash flows from operating leases ​ $ 2,533 ​ $ 2,124 Financing cash flows from finance leases ​ $ 780 ​ $ 720 ​
Schedule of weighted-average remaining lease term and weighted-average discount rate	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 June 30, 2020 ​ Weighted-average remaining lease term (years) ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ 6.2 ​ ​ 7.0 ​ Finance leases ​ ​ N/A ​ ​ 5.5 ​ Weighted-average discount rate ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ 8% ​ ​ 8% ​ Finance leases ​ ​ N/A ​ ​ 8% ​
Schedule of future minimum commitments due under lease agreements	​ ​ ​ ​ ​ ​ ​ ​ ​ Operating Leases ​ ​ 2021 (remaining six months) ​ 2,842 ​ 2022 ​ 5,249 ​ 2023 ​ 4,690 ​ 2024 ​ ​ 4,686 ​ ​ 2025 ​ ​ 4,843 ​ ​ Thereafter ​ 9,972 ​ Present value adjustment ​ ​ (7,126) ​ ​ Present value of lease payments ​ $ 25,156 ​ ​

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2021
Long-term Debt
Schedule of Future Annual Principal Payments on Convertible Senior Notes	The following is a summary of our convertible senior notes at June 30, 2021 and December 31, 2020 (principal amount in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Principal Amount ​ Principal Amount ​ ​ ​ ​ ​ Conversion rate per $1,000 ​ ​ June 30, 2021 ​ December 31, 2020 ​ Interest Rate ​ Maturity Date ​ principal amount (shares) 2021 Notes ​ $ 64,418 ​ $ 64,418 ​ 2.50% ​ September 15, 2021 ​ 16.1616 2024 Notes (2019 Issuance) ​ 85,782 ​ 85,782 ​ 4.50% ​ August 1, 2024 ​ 137.2213 2024 Notes (2020 Issuance) ​ ​ 57,500 ​ ​ 57,500 ​ 4.50% ​ August 1, 2024 ​ 160.3334 2025 Notes ​ 300,000 ​ 300,000 ​ 1.25% ​ May 1, 2025 ​ 13.1278 Total ​ ​ 507,700 ​ ​ 507,700 ​ ​ ​ ​ ​ ​ Unamortized debt issuance costs ​ ​ (7,588) ​ ​ (8,656) ​ ​ ​ ​ ​ ​ Convertible senior notes ​ $ 500,112 ​ $ 499,044 ​ ​ ​ ​ ​ ​
Schedule of Total Interest Expense Recognized Related to Notes	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended June 30, ​ Six months ended June 30, ​ ​ 2021 2020 2021 2020 Interest on convertible notes ​ $ 2,952 ​ $ 2,811 ​ $ 5,929 ​ $ 5,994 ​ Amortization of debt issuance costs ​ 622 ​ 637 ​ 1,260 ​ 1,423 ​ Debt issuance cost derecognized related to convertible debt transactions ​ ​ — ​ ​ 789 ​ ​ — ​ ​ 4,344 ​ Interest on finance lease ​ ​ 178 ​ ​ 208 ​ ​ 363 ​ ​ 423 ​ Interest on borrowings under financing agreement ​ ​ 4,993 ​ ​ 2,264 ​ ​ 9,203 ​ ​ 4,055 ​ Other interest ​ ​ 25 ​ ​ 30 ​ ​ 52 ​ ​ 61 ​ Total interest expense ​ $ 8,770 ​ $ 6,739 ​ $ 16,807 ​ $ 16,300 ​

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2021
Stockholders' Equity
Component of Other Comprehensive Income (Loss)	The changes in accumulated balances related to each component of other comprehensive income (loss) are summarized for the three months ended June 30, 2021 and 2020, as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Foreign Currency ​ Unrealized ​ Total Accumulated ​ ​ Translation Adjustments ​ (Losses) Gains ​ Other Comprehensive Loss ​ ​ 2021 ​ 2020 ​ 2021 ​ 2020 ​ 2021 ​ 2020 ​ Balance at April 1, ​ $ (44,245) ​ $ (44,835) ​ $ (139) ​ $ (55) ​ $ (44,384) ​ $ (44,890) ​ Other comprehensive income (loss) ​ ​ 14 ​ ​ 61 ​ ​ — ​ ​ (84) ​ ​ 14 ​ ​ (23) ​ Total before tax ​ ​ (44,231) ​ ​ (44,774) ​ ​ (139) ​ ​ (139) ​ ​ (44,370) ​ ​ (44,913) ​ Tax effect ​ — ​ ​ — ​ — ​ ​ — ​ — ​ ​ — ​ Balance at June 30, ​ $ (44,231) ​ $ (44,774) ​ $ (139) ​ $ (139) ​ $ (44,370) ​ $ (44,913) ​ ​ The changes in accumulated balances related to each component of other comprehensive income (loss) are summarized for the six months ended June 30, 2021 and 2020, as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Foreign Currency ​ Unrealized ​ Total Accumulated ​ ​ Translation Adjustments ​ (Losses) Gains ​ Other Comprehensive Loss ​ ​ 2021 ​ 2020 ​ 2021 ​ 2020 ​ 2021 ​ 2020 ​ Balance at January 1, ​ $ (44,165) ​ $ (44,732) ​ $ (139) ​ $ (133) ​ $ (44,304) ​ $ (44,865) ​ Other comprehensive (loss) income ​ ​ (66) ​ ​ (42) ​ ​ — ​ ​ (6) ​ ​ (66) ​ ​ (48) ​ Total before tax ​ ​ (44,231) ​ ​ (44,774) ​ ​ (139) ​ ​ (139) ​ ​ (44,370) ​ ​ (44,913) ​ Tax effect ​ — ​ ​ — ​ — ​ ​ — ​ — ​ ​ — ​ Balance at June 30, ​ $ (44,231) ​ $ (44,774) ​ $ (139) ​ $ (139) ​ $ (44,370) ​ $ (44,913) ​

Share-Based Compensation (Table

Share-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2021
Share-Based Compensation
Share-Based Compensation Expense Recognized in Accompanying Statements of Operations	Share-based compensation expense for all equity-based programs, including stock options, restricted stock units and the employee stock purchase plan, for the three and six months ended June 30, 2021 and 2020 was recognized in the accompanying Consolidated Statements of Operations and Comprehensive Loss as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended June 30, ​ Six months ended June 30, ​ ​ 2021 2020 2021 2020 Research and development ​ $ 3,474 ​ $ 6,636 ​ $ 6,350 ​ $ 13,561 ​ ​ Selling, general and administrative ​ 3,888 ​ 6,677 ​ 5,051 ​ 12,713 ​ ​ Total share-based compensation expense ​ $ 7,362 ​ $ 13,313 ​ $ 11,401 ​ $ 26,274 ​ ​
Summary of Stock Options Activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ Weighted ​ Average ​ Aggregate ​ ​ ​ ​ Average ​ Remaining ​ Intrinsic ​ ​ Number of ​ Exercise ​ Contractual ​ Value ​ ​ Options ​ Price ​ Term (Years) ​ (Thousands) Outstanding at December 31, 2020 ​ 6,502,169 ​ $ 37.78 ​ ​ Granted ​ 1,017,132 ​ ​ 6.11 ​ ​ Exercised ​ (7,087) ​ ​ 4.98 ​ ​ Forfeited ​ (316,917) ​ ​ 39.02 ​ ​ Outstanding at June 30, 2021 ​ 7,195,297 ​ $ 33.28 5.8 ​ $ 309 ​ Vested and expected to vest at June 30, 2021 ​ 7,007,820 ​ $ 33.93 5.7 ​ $ 277 ​ Vested and exercisable at June 30, 2021 ​ 5,440,479 ​ $ 40.40 4.8 ​ $ 84 ​
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award	The following table summarizes information about our stock options as of and for the three and six months ended June 30, 2021 and 2020 (in thousands, except per share amounts): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended June 30, ​ Six months ended June 30, ​ ​ 2021 2020 2021 2020 Weighted-average grant date fair value per share ​ $ 4.72 ​ $ 5.06 ​ $ 4.85 ​ $ 5.87 ​ Intrinsic value of options exercised ​ $ 1 ​ $ 87 ​ $ 15 ​ $ 91 ​ Cash received from stock option exercises ​ $ 8 ​ $ 72 ​ $ 35 ​ $ 74 ​
Summary of activity related to our unvested RSUs	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average ​ ​ Number of ​ Grant Date ​ ​ Units ​ Fair Value Unvested at December 31, 2020 ​ 2,964,297 ​ $ 14.36 ​ Granted ​ 2,631,278 ​ 6.22 ​ Vested ​ (1,047,175) ​ 16.73 ​ Forfeited ​ (294,733) ​ 9.10 ​ Unvested at June 30, 2021 ​ 4,253,667 ​ $ 9.11 ​ Expected to vest after June 30, 2021 ​ 3,655,671 ​ $ 9.35 ​

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	6 Months Ended
	Jun. 30, 2021
Net Loss Per Common Share
Shares Outstanding Excluded from Calculation of Diluted Net Loss Per Share	The shares outstanding at the end of the respective periods presented in the table below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ Three and six months ended June 30, ​ ​ 2021 2020 Common shares under stock incentive plans ​ 4,524 ​ 4,156 ​ Convertible senior notes ​ 25,969 ​ 25,648 ​ Total potential dilutive shares ​ 30,493 ​ 29,804 ​

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Jun. 30, 2021
Segment Information
Schedule of information about reportable segments	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended June 30, ​ 2021 ​ 2020 ​ ​ U.S. Ex-U.S. Total U.S. Ex-U.S. Total Product revenue ​ $ 27,680 ​ $ 9,140 ​ $ 36,820 ​ $ 36,719 ​ $ 3,168 ​ $ 39,887 ​ Operating expenses: ​ ​ ​ ​ ​ ​ ​ Cost of sales - product ​ 5,402 ​ 2,892 ​ 8,294 ​ 7,522 ​ 1,598 ​ 9,120 ​ Cost of sales - intangible asset amortization ​ 620 ​ 723 ​ 1,343 ​ 557 ​ 723 ​ 1,280 ​ Research and development ​ 43,774 ​ 1,985 ​ 45,759 ​ 67,862 ​ 2,016 ​ 69,878 ​ Selling, general and administrative ​ 26,351 ​ 6,567 ​ 32,918 ​ 35,969 ​ 5,933 ​ 41,902 ​ Acquired in-process research and development ​ ​ 2,204 ​ ​ — ​ ​ 2,204 ​ ​ — ​ ​ — ​ ​ — ​ Other operating expenses ​ ​ 3,884 ​ ​ — ​ ​ 3,884 ​ ​ 355 ​ ​ — ​ ​ 355 ​ Total expenses ​ 82,235 12,167 94,402 112,265 10,270 122,535 Operating loss ​ $ (54,555) ​ $ (3,027) ​ ​ (57,582) ​ $ (75,546) ​ $ (7,102) ​ ​ (82,648) ​ Other income (expense): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Interest expense ​ ​ ​ ​ ​ ​ ​ ​ (8,770) ​ ​ ​ ​ ​ ​ ​ ​ (6,739) ​ Foreign currency (loss) gain ​ ​ ​ ​ ​ ​ ​ ​ (206) ​ ​ ​ ​ ​ ​ ​ ​ 142 ​ Loss on extinguishment of debt ​ ​ ​ ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ ​ ​ ​ (3,277) ​ Other income ​ ​ ​ ​ ​ ​ ​ ​ 107 ​ ​ ​ ​ ​ ​ ​ ​ 239 ​ Other income (expense), net ​ ​ ​ ​ ​ ​ ​ ​ (8,869) ​ ​ ​ ​ ​ ​ ​ ​ (9,635) ​ Loss before income taxes ​ ​ ​ ​ ​ ​ ​ ​ (66,451) ​ ​ ​ ​ ​ ​ ​ ​ (92,283) ​ Income tax benefit ​ ​ ​ ​ ​ ​ ​ ​ 3 ​ ​ ​ ​ ​ ​ ​ ​ 36 ​ Net loss ​ ​ ​ ​ ​ ​ ​ $ (66,448) ​ ​ ​ ​ ​ ​ ​ $ (92,247) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six months ended June 30, ​ 2021 ​ 2020 ​ ​ U.S. Ex-U.S. Total U.S. Ex-U.S. Total Product revenue ​ $ 59,381 ​ $ 15,492 ​ $ 74,873 ​ $ 76,022 ​ $ 6,429 ​ $ 82,451 ​ Operating expenses: ​ ​ ​ ​ ​ ​ ​ Cost of sales - product ​ 11,560 ​ 5,002 ​ 16,562 ​ 15,577 ​ 2,639 ​ 18,216 ​ Cost of sales - intangible asset amortization ​ 1,241 ​ 1,445 ​ 2,686 ​ 1,047 ​ 1,445 ​ 2,492 ​ Research and development ​ 94,604 ​ 3,960 ​ 98,564 ​ 134,149 ​ 3,950 ​ 138,099 ​ Selling, general and administrative ​ 50,672 ​ 12,187 ​ 62,859 ​ 72,124 ​ 12,376 ​ 84,500 ​ Acquired in-process research and development ​ ​ 2,204 ​ ​ — ​ ​ 2,204 ​ ​ — ​ ​ — ​ ​ — ​ Other operating expenses ​ ​ 7,591 ​ ​ — ​ ​ 7,591 ​ ​ 3,805 ​ ​ — ​ ​ 3,805 ​ Total expenses ​ 167,872 22,594 190,466 226,702 20,410 247,112 Operating loss ​ $ (108,491) ​ $ (7,102) ​ ​ (115,593) ​ $ (150,680) ​ $ (13,981) ​ ​ (164,661) ​ Other income (expense): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Interest expense ​ ​ ​ ​ ​ ​ ​ ​ (16,807) ​ ​ ​ ​ ​ ​ ​ ​ (16,300) ​ Foreign currency loss ​ ​ ​ ​ ​ ​ ​ ​ (752) ​ ​ ​ ​ ​ ​ ​ ​ (735) ​ Loss on convertible senior notes conversion ​ ​ ​ ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ ​ ​ ​ (7,791) ​ Loss on extinguishment of debt ​ ​ ​ ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ ​ ​ ​ (3,277) ​ Other income ​ ​ ​ ​ ​ ​ ​ ​ 290 ​ ​ ​ ​ ​ ​ ​ ​ 1,081 ​ Other income (expense), net ​ ​ ​ ​ ​ ​ ​ ​ (17,269) ​ ​ ​ ​ ​ ​ ​ ​ (27,022) ​ Loss before income taxes ​ ​ ​ ​ ​ ​ ​ ​ (132,862) ​ ​ ​ ​ ​ ​ ​ ​ (191,683) ​ Income tax benefit ​ ​ ​ ​ ​ ​ ​ ​ 137 ​ ​ ​ ​ ​ ​ ​ ​ 104 ​ Net loss ​ ​ ​ ​ ​ ​ ​ $ (132,725) ​ ​ ​ ​ ​ ​ ​ $ (191,579) ​

Nature of Business (Details)

Nature of Business (Details)	6 Months Ended
	Jun. 30, 2021itemproductsegment
Number of operating segments | segment	2
Number of other product candidates | product	2
Minimum
Number of chemotherapies received by an adult patient	2
Number of prior lines of platinum based chemotherapy received by patient	2

Summary of Significant Policies

Summary of Significant Policies (Details)	6 Months Ended
	Jun. 30, 2021segment
Schedule Of Significant Accounting Policies
Amortization period of the asset	true
Payment terms number of days	30 days
Shelf-life of API	4 years
Consumption period of API	6 years
Number Of Operating Segments	2
Number of Reportable Segments	2
Rucaparib
Schedule Of Significant Accounting Policies
Shelf life of inventory	4 years

Financial Instruments and Fai_3

Financial Instruments and Fair Value Measurements (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Fair Value Measurements
Liabilities at fair value	$ 0
Recurring
Fair Value Measurements
Assets at fair value	132,928	$ 147,921
Money Market | Recurring
Fair Value Measurements
Assets at fair value	132,928	147,921
Fair Value, Inputs, Level 1 | Recurring
Fair Value Measurements
Assets at fair value	132,928	147,921
Fair Value, Inputs, Level 1 | Money Market | Recurring
Fair Value Measurements
Assets at fair value	132,928	147,921
Fair Value, Inputs, Level 2 | Money Market | Recurring
Fair Value Measurements
Assets at fair value	0	0
Fair Value, Inputs, Level 3 | Recurring
Fair Value Measurements
Assets at fair value	0	0
Fair Value, Inputs, Level 3 | Money Market | Recurring
Fair Value Measurements
Assets at fair value	$ 0	$ 0

Financial Instruments and Fai_4

Financial Instruments and Fair Value Measurements - Additional Information (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Fair Value Measurements
Current portion	$ 64,353	$ 64,198
Principal amount outstanding	500,112	$ 499,044
Convertible Senior Unsecured Notes 2021 Notes
Fair Value Measurements
Current portion	64,400
Convertible senior notes, fair value	63,100
2024 Notes (2019 Issuance)
Fair Value Measurements
Convertible senior notes, fair value	90,300
Principal amount outstanding	84,200
2024 Notes (2020 Issuance)
Fair Value Measurements
Convertible senior notes, fair value	60,200
Principal amount outstanding	56,700
Convertible Senior Unsecured Notes 2025 Notes
Fair Value Measurements
Convertible senior notes, fair value	223,200
Principal amount outstanding	$ 294,900

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Inventories
Work-in-process	$ 94,138	$ 102,507
Finished goods, net	34,901	32,330
Total inventories	129,039	134,837
Current inventory	24,993	30,714
Long-term inventory	$ 104,046	$ 104,123

Other Current Assets (Details)

Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Other Current Assets
Prepaid insurance	$ 2,485	$ 782
Prepaid IT	553	753
Prepaid variable considerations	440	1,191
Prepaid expenses - other	3,852	2,193
Value-added tax ("VAT") receivable	3,545	2,202
Receivable - other	2,101	1,884
Other	80	125
Total	$ 13,056	$ 9,130

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill (Details) - Licensing Agreements - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Finite Lived Intangible Assets [Line Items]
Intangible asset - milestones	$ 79,850	$ 79,850
Accumulated amortization	(16,793)	(14,107)
Total intangible asset, net	$ 63,057	$ 65,743

Intangible Assets and Goodwil_3

Intangible Assets and Goodwill - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Licensing Agreements
Finite Lived Intangible Assets
Amortization of Intangible Assets	$ 1.3	$ 1.3	$ 2.7	$ 2.5

Intangible Assets and Goodwil_4

Intangible Assets and Goodwill - Estimated Future Amortization (Details) - Licensing Agreements - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Finite Lived Intangible Assets
2021 (remaining six months)	$ 2,686
2022	5,371
2023	5,371
2024	5,371
2025	5,371
Thereafter	38,887
Total intangible asset, net	$ 63,057	$ 65,743

Other Accrued Expenses (Details

Other Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Other Accrued Expenses
Accrued personnel costs	$ 12,058	$ 18,334
Accrued interest payable for convertible senior notes	3,753	2,991
Income tax payable	1,340	907
Accrued corporate legal fees and professional services	280	459
Accrued royalties	5,579	6,617
Accrued variable considerations	13,901	11,701
Accrued expenses - other	6,499	4,199
Total	$ 43,410	$ 45,208

Leases (Details)

Leases (Details) - USD ($) $ in Thousands	Jun. 16, 2021	Jun. 30, 2021
Lessee, Lease, Description [Line Items]
Payments on derecognition of lease components	$ 1,100	$ 1,100
Impairment of prepaid manufacturing costs		0
Other operating expense
Lessee, Lease, Description [Line Items]
Loss on derecognition of fixed assets		$ 300

Leases - Components of lease ex

Leases - Components of lease expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Lessee Disclosure [Abstract]
Amortization of right-of-use assets	$ 474	$ 474	$ 947	$ 947
Interest on lease liabilities	178	208	363	423
Operating lease cost	1,280	998	2,533	2,124
Short-term lease cost	80	116	160	222
Variable lease cost	640	472	1,163	1,070
Total lease cost	2,652	2,268	5,166	4,786
Cash flows from leases
Operating cash flows from finance leases	178	208	363	423
Operating cash flows from operating leases	1,280	998	2,533	2,124
Financing cash flows from finance leases	$ 394	$ 364	$ 780	$ 720

Leases - Weighted Average (Deta

Leases - Weighted Average (Details)	Jun. 30, 2021	Jun. 30, 2020
Weighted-average remaining lease term (years)
Operating leases	6 years 2 months 12 days	7 years
Finance leases		5 years 6 months
Weighted-average discount rate
Operating leases	8.00%	8.00%
Finance leases		8.00%

Leases - Future minimum commitm

Leases - Future minimum commitments (Details) $ in Thousands	Jun. 30, 2021USD ($)
Operating Leases
2021 (remaining six months)	$ 2,842
2021	5,249
2022	4,690
2023	4,686
2024	4,843
Thereafter	9,972
Present value adjustment	(7,126)
Present value of lease payments	$ 25,156
Operating Lease, Liability, Statement of Financial Position [Extensible List]	us-gaap:OtherLiabilitiesCurrent, us-gaap:OtherLiabilitiesNoncurrent

Debt (Details)

Debt (Details) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Dec. 31, 2020USD ($)	May 01, 2019USD ($)
Debt Instrument
Aggregate principal amount		$ 507,700		$ 507,700
Unamortized debt issuance costs		(7,588)		(8,656)
Principal amount outstanding		500,112		499,044
Gain (loss) on extinguishment of debt	$ (3,277)		$ (3,277)
Sixth Street Partners, LLC
Debt Instrument
Aggregate principal amount		175,000
Unamortized debt issuance costs		(1,400)
Principal amount outstanding		147,400
Quarterly payments based on a certain percentage of revenues		$ 8,500
Percentage of direct worldwide sales that determine quarterly payments		9.75%
Debt issuance costs		$ 1,800
Effective interest rate		14.60%
Ratio of repayment amount		2
Sixth Street Partners, LLC | Maximum
Debt Instrument
Aggregate principal amount					$ 175,000
Maximum amount required to be repaid		$ 350,000
2021 Notes
Debt Instrument
Aggregate principal amount		$ 64,418		64,418
Convertible senior notes, interest rate		2.50%
Convertible senior notes, maturity date		Sep. 15, 2021
Conversion rate per $1,000 principal amount (shares)		16.1616
2024 Notes (2019 Issuance)
Debt Instrument
Aggregate principal amount		$ 85,782		85,782
Convertible senior notes, interest rate		4.50%
Convertible senior notes, maturity date		Aug. 1, 2024
Conversion rate per $1,000 principal amount (shares)		137.2213
Principal amount outstanding		$ 84,200
2024 Notes (2020 Issuance)
Debt Instrument
Aggregate principal amount		$ 57,500		57,500
Convertible senior notes, interest rate		4.50%
Convertible senior notes, maturity date		Aug. 1, 2024
Conversion rate per $1,000 principal amount (shares)		160.3334
Principal amount outstanding		$ 56,700
2025 Notes
Debt Instrument
Aggregate principal amount		$ 300,000		$ 300,000
Convertible senior notes, interest rate		1.25%
Convertible senior notes, maturity date		May 1, 2025
Conversion rate per $1,000 principal amount (shares)		13.1278

Debt - Interest expense recogni

Debt - Interest expense recognized (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Long-term Debt
Interest on convertible notes	$ 2,952	$ 2,811	$ 5,929	$ 5,994
Amortization of debt issuance costs	622	637	1,260	1,423
Debt issuance cost derecognized related to convertible debt transactions		789		4,344
Interest on finance lease	178	208	363	423
Interest on borrowings under financing agreement	4,993	2,264	9,203	4,055
Other interest	25	30	52	61
Total interest expense	$ 8,770	$ 6,739	$ 16,807	$ 16,300

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details) $ in Thousands	May 17, 2021USD ($)	Jun. 09, 2021USD ($)shares	Jun. 30, 2021USD ($)Vote	Jun. 30, 2020USD ($)
Class Of Stock [Line Items]
Number of votes per common share | Vote			1
Proceeds from offering			$ 72,472	$ 246,727
At the market offering
Class Of Stock [Line Items]
Aggregate offering price	$ 75,000
Common shares issued in a public offering | shares		13,492,231
Gross proceeds from offering		$ 75,000
Proceeds from offering		$ 72,500

Stockholders' Equity - Accumula

Stockholders' Equity - Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Accumulated Other Comprehensive Loss
Beginning balance	$ (44,384)	$ (44,890)	$ (44,304)	$ (44,865)
Other comprehensive income (loss)	14	(23)	(66)	(48)
Total before tax	(44,370)	(44,913)	(44,370)	(44,913)
Tax effect	0	0
Ending balance	(44,370)	(44,913)	(44,370)	(44,913)
Reclassifications out of accumulated other comprehensive loss	0	0	0	0
Foreign Currency Translation Adjustments
Accumulated Other Comprehensive Loss
Beginning balance	(44,245)	(44,835)	(44,165)	(44,732)
Other comprehensive income (loss)	14	61	(66)	(42)
Total before tax	(44,231)	(44,774)	(44,231)	(44,774)
Tax effect	0	0
Ending balance	(44,231)	(44,774)	(44,231)	(44,774)
Unrealized Losses
Accumulated Other Comprehensive Loss
Beginning balance	(139)	(55)	(139)	(133)
Other comprehensive income (loss)		(84)		(6)
Total before tax	(139)	(139)	(139)	(139)
Tax effect	0	0
Ending balance	$ (139)	$ (139)	$ (139)	$ (139)

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share Based Compensation Arrangement By Share Based Payment Award
Share-based compensation expense, tax benefit recognized	$ 0	$ 0	$ 0	$ 0
Closing stock price	$ 5.80		$ 5.80
Stock-based compensation expense	$ 7,362	$ 13,313	$ 11,401	$ 26,274
Common shares under stock incentive plans
Share Based Compensation Arrangement By Share Based Payment Award
Unrecognized stock-based compensation expense related to unvested stock options	14,100		$ 14,100
Unrecognized stock-based compensation expense related to non-vested options and/or RSUs, weighted-average remaining vesting period			1 year 7 months 6 days
Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award
Unrecognized stock-based compensation expense related to non-vested options and/or RSUs, weighted-average remaining vesting period			2 years 3 months 18 days
Weighted-average estimated grant date fair value of purchase awards under Purchase Plan			$ 16.73
Unrecognized stock-based compensation expense related to unvested RSUs	$ 35,300		$ 35,300

Share-Based Compensation - Shar

Share-Based Compensation - Share-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-Based Compensation Expense Recognized in Accompanying Statements of Operations
Total Share-based compensation expense	$ 7,362	$ 13,313	$ 11,401	$ 26,274
Research and development
Share-Based Compensation Expense Recognized in Accompanying Statements of Operations
Total Share-based compensation expense	3,474	6,636	6,350	13,561
General and administrative
Share-Based Compensation Expense Recognized in Accompanying Statements of Operations
Total Share-based compensation expense	$ 3,888	$ 6,677	$ 5,051	$ 12,713

Share-Based Compensation - Summ

Share-Based Compensation - Summary of Stock Options Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2021
Share-Based Compensation
Beginning Balance, Number of Options Outstanding	6,502,169
Granted, Number of Options	1,017,132
Exercised, Number of Options	(7,087)
Forfeited, Number of Options	(316,917)
Ending Balance, Number of Options Outstanding	7,195,297
Vested and expected to vest, Number of Options Outstanding	7,007,820
Vested and exercisable, Number of Options Outstanding	5,440,479
Beginning Balance, Weighted Average Exercise Price	$ 37.78
Granted, Weighted Average Exercise Price	6.11
Exercised, Weighted Average Exercise Price	4.98
Forfeited, Weighted Average Exercise Price	39.02
Ending Balance, Weighted Average Exercise Price	33.28
Vested and expected to vest, Weighted Average Exercise Price	33.93
Vested and exercisable, Weighted Average Exercise Price	$ 40.40
Outstanding, Weighted Average Remaining Contractual Term (Years)	5 years 9 months 18 days
Vested and expected to vest, Weighted Average Remaining Contractual Term (Years)	5 years 8 months 12 days
Vested and exercisable, Weighted Average Remaining Contractual Term (Years)	4 years 9 months 18 days
Outstanding, Aggregate Intrinsic Value	$ 309
Vested and expected to vest, Aggregate Intrinsic Value	277
Vested and exercisable, Aggregate Intrinsic Value	$ 84

Share-Based Compensation - Sche

Share-Based Compensation - Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-Based Compensation
Weighted-average grant date fair value per share	$ 4.72	$ 5.06	$ 4.85	$ 5.87
Intrinsic value of options exercised	$ 1	$ 87	$ 15	$ 91
Cash received from stock option exercises	$ 8	$ 72	$ 35	$ 74

Share-Based Compensation - RSUs

Share-Based Compensation - RSUs Activity (Details) - Restricted Stock Units (RSUs)	6 Months Ended
	Jun. 30, 2021$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award
Number of Units, Unvested as of Beginning Balance | shares	2,964,297
Number of Units, Granted | shares	2,631,278
Number of Units, Vested | shares	(1,047,175)
Number of Units, Forfeited | shares	(294,733)
Number of Units, Unvested as of Ending Balance | shares	4,253,667
Expected to vest after December 31, 2020 | shares	3,655,671
Weighted Average Grant Date Fair Value, Beginning Balance | $ / shares	$ 14.36
Weighted Average Grant Date Fair Value, Granted | $ / shares	6.22
Weighted Average Grant Date Fair Value, Vested | $ / shares	16.73
Weighted Average Grant Date Fair Value, Forfeited | $ / shares	9.10
Weighted Average Grant Date Fair Value, Ending Balance | $ / shares	9.11
Weighted Average Grant Date Fair Value, Expected to vest after December 31, 2020 | $ / shares	$ 9.35

License Agreements (Details)

License Agreements (Details) $ in Millions	Nov. 19, 2013USD ($)	Apr. 30, 2021USD ($)	Feb. 29, 2020item	Sep. 30, 2019USD ($)	Jun. 30, 2011USD ($)	Oct. 31, 2008	Jun. 30, 2021USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2020USD ($)
3B Pharmaceuticals
License Agreements
Percentage of Non-Royalty Consideration Payable on Sublicense Agreements							34.00%
License Agreements Licensor Pfizer | Rucaparib | Minimum
License Agreements
Annual sales target for sales milestone payments							$ 250
License Agreements Licensor Pfizer | Rucaparib | Maximum
License Agreements
Maximum potential future development, regulatory milestone payments							8
Additional maximum payments payable on attaining the sales target							$ 170
License Agreement Terms | 3B Pharmaceuticals
License Agreements
Milestone payments		$ 2.2
Acquired in-process research and development				$ 9.4
Number of additional undisclosed targets | item			3
Research and development expense								$ 2.1
Percentage Of Royalty On Net Sales							6.00%
License Agreement Terms | License Agreements Licensor Pfizer | Rucaparib
License Agreements
Upfront payment					$ 7
Milestones paid to Pfizer prior to FDA approval					$ 1.4
Milestone payments									$ 82.5
License Agreement Terms | Advenchen Laboratories LLC | License Agreements Lucitanib
License Agreements
Milestone payment obligation	$ 65
Percentage of Non-Royalty Consideration Payable on Sublicense Agreements						25.00%

Net Loss Per Common Share (Deta

Net Loss Per Common Share (Details) - shares shares in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Antidilutive Securities Excluded From Computation Of Earnings Per Share
Total potential dilutive shares	30,493	29,804
Common shares under stock incentive plans
Antidilutive Securities Excluded From Computation Of Earnings Per Share
Total potential dilutive shares	4,524	4,156
Convertible senior notes
Antidilutive Securities Excluded From Computation Of Earnings Per Share
Total potential dilutive shares	25,969	25,648

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Thousands	Jun. 16, 2021USD ($)	Nov. 10, 2019plaintiff	Jun. 20, 2017patent	Mar. 31, 2017shareholder	Jun. 30, 2021USD ($)
Purchase commitments					$ 49,400
Payments on derecognition of lease components	$ 1,100				1,100
Impairment of prepaid manufacturing costs					0
Number of putative shareholders | shareholder				2
Number of patents in salt and polymorph patent family | patent			2
Number of opponents | plaintiff		1
Other operating expense
Loss on derecognition of fixed assets					$ 300

Segment Information - Reportabl

Segment Information - Reportable segments (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020
Segment Reporting Information [Line Items]
Product revenue	$ 36,820		$ 39,887		$ 74,873	$ 82,451
Product revenue - extensible list	Product		Product		Product	Product
Operating expenses:
Research and development	$ 45,759		$ 69,878		$ 98,564	$ 138,099
Selling, general and administrative	32,918		41,902		62,859	84,500
Acquired in-process research and development	2,204				2,204
Other operating expenses	3,884		355		7,591	3,805
Total expenses	94,402		122,535		190,466	247,112
Operating loss	(57,582)		(82,648)		(115,593)	(164,661)
Other income (expense):
Interest expense	(8,770)		(6,739)		(16,807)	(16,300)
Foreign currency (loss) gain	(206)		142		(752)	(735)
Loss on convertible senior notes conversion						(7,791)
Loss on extinguishment of debt			(3,277)			(3,277)
Other income	107		239		290	1,081
Other income (expense), net	(8,869)		(9,635)		(17,269)	(27,022)
Loss before income taxes	(66,451)		(92,283)		(132,862)	(191,683)
Income tax benefit	3		36		137	104
Net loss	(66,448)	$ (66,277)	(92,247)	$ (99,332)	(132,725)	(191,579)
Product
Operating expenses:
Cost of sales	8,294		9,120		16,562	18,216
Intangible asset amortization
Operating expenses:
Cost of sales	1,343		1,280		2,686	2,492
U.S.
Segment Reporting Information [Line Items]
Product revenue	$ 27,680		$ 36,719		59,381	76,022
Product revenue - extensible list	Product		Product
Operating expenses:
Research and development	$ 43,774		$ 67,862		94,604	134,149
Selling, general and administrative	26,351		35,969		50,672	72,124
Acquired in-process research and development	2,204				2,204
Other operating expenses	3,884		355		7,591	3,805
Total expenses	82,235		112,265		167,872	226,702
Operating loss	(54,555)		(75,546)		(108,491)	(150,680)
U.S. | Product
Operating expenses:
Cost of sales	5,402		7,522		11,560	15,577
U.S. | Intangible asset amortization
Operating expenses:
Cost of sales	620		557		1,241	1,047
ex U.S.
Segment Reporting Information [Line Items]
Product revenue	$ 9,140		$ 3,168		15,492	6,429
Product revenue - extensible list	Product		Product
Operating expenses:
Research and development	$ 1,985		$ 2,016		3,960	3,950
Selling, general and administrative	6,567		5,933		12,187	12,376
Total expenses	12,167		10,270		22,594	20,410
Operating loss	(3,027)		(7,102)		(7,102)	(13,981)
ex U.S. | Product
Operating expenses:
Cost of sales	2,892		1,598		5,002	2,639
ex U.S. | Intangible asset amortization
Operating expenses:
Cost of sales	$ 723		$ 723		$ 1,445	$ 1,445